EP0845997A1 - Formulation de proteine lyophilisee isotonique et stable - Google Patents

Formulation de proteine lyophilisee isotonique et stable

Info

Publication number
EP0845997A1
EP0845997A1 EP96925497A EP96925497A EP0845997A1 EP 0845997 A1 EP0845997 A1 EP 0845997A1 EP 96925497 A EP96925497 A EP 96925497A EP 96925497 A EP96925497 A EP 96925497A EP 0845997 A1 EP0845997 A1 EP 0845997A1
Authority
EP
European Patent Office
Prior art keywords
formulation
protein
antibody
reconstituted
lyophilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96925497A
Other languages
German (de)
English (en)
Inventor
James Andya
Jeffrey L. Cleland
Chung C. Hsu
Xanthe M. Lam
David E. Overcashier
Steven J. Shire
Janet Yu-Feng Yang
Sylvia Sau-Yan Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27056058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0845997(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/615,369 external-priority patent/US6267958B1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to EP04022777.9A priority Critical patent/EP1516628B1/fr
Priority to DK04022777.9T priority patent/DK1516628T3/da
Priority to EP10178416.3A priority patent/EP2275119B1/fr
Publication of EP0845997A1 publication Critical patent/EP0845997A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention is directed to a lyophilized protein formulation.
  • it relates to a stable lyophilized protein formulation which can be reconstituted with a diluent to generate a stable reconstituted formulation suitable for subcutaneous administration.
  • proteins are larger and more complex than traditional organic and inorganic drugs (i.e. possessing multiple functional groups in addition to complex three-dimensional structures), the formulation of such proteins poses special problems.
  • a formulation must preserve intact the conformational integrity of at least a core sequence ofthe protein's amino acids while at the same time protecting the protein's multiple functional groups from degradation.
  • Degradation pathways for proteins can involve chemical instability (i.e. any process which involves modification of the protein by bond formation or cleavage resulting in a new chemical entity) or physical instability (i.e. changes in the higher order structure ofthe protein).
  • Chemical instability can result from deamidation, racemization, hydrolysis, oxidation, beta elimination or disulfide exchange. Physical instability can result from denaturation. aggregation, precipitation or adsorption, for example. The three most common protein degradation pathways are protein aggregation, deamidation and oxidation. Cleland et al. Critical Reviews in Therapeutic Drug Carrier Systems 10(4): 307-377 (1993).
  • Freeze-drying is a commonly employed technique for preserving proteins which serves to remove water from the protein preparation of interest.
  • Freeze-drying or lyophilization, is a process by which the material to be dried is first frozen and then the ice or frozen solvent is removed by sublimation in a vacuum environment.
  • An excipient may be included in pre-lyophilized formulations to enhance stability during the freeze-drying process and/or to improve stability ofthe lyophilized product upon storage. Pikal, M. Biopharm. 3(9)26-30 (1990) and Arakawa e/ ⁇ t Pharm. Res. 8(3):285-291 (1991).
  • a stable lyophilized protein formulation can be prepared using a lyoprotectant (preferably a sugar such as sucrose or trehalose), which lyophilized formulation can be reconstituted to generate a stable reconstituted formulation having a protein concentration which is significantly higher (e.g. from about 2-40 times higher, preferably 3-10 times higher and most preferably 3-6 times higher) than the protein concentration in the pre-lyophilized formulation.
  • a lyoprotectant preferably a sugar such as sucrose or trehalose
  • the protein concentration in the pre-lyophilized formulation may be 5 mg/mL or less
  • the protein concentration in the reconstituted formulation is generally 50 mg/mL or more.
  • Such high protein concentrations in the reconstituted formulation are considered to be particularly useful where the formulation is intended for subcutaneous administration.
  • the reconstituted formulation is stable (i.e. fails to display significant or unacceptable levels of chemical or physical instability of the protein) at 2-8 ° C for at least about 30 days.
  • the reconstituted formulation is isotonic.
  • the protein in the lyophilized formulation essentially retains its physical and chemical stability and integrity upon lyophilization and storage.
  • the reconstituted formulation When reconstituted with a diluent comprising a preservative (such as bacteriostatic water for injection, BWFI), the reconstituted formulation may be used as a multi-use formulation.
  • a diluent comprising a preservative (such as bacteriostatic water for injection, BWFI)
  • BWFI bacteriostatic water for injection
  • the reconstituted formulation may be used as a multi-use formulation.
  • a formulation is useful, for example, where the patient requires frequent subcutaneous administrations of the protein to treat a chronic medical condition.
  • the advantage of a multi-use formulation is that it facilitates ease of use for the patient, reduces waste by allowing complete use of vial contents, and results in a significant cost savings for the manufacturer since several doses are packaged in a single vial (lower filling and shipping costs).
  • the invention provides a stable isotonic reconstituted formulation comprising a protein in an amount of at least about 50 mg mL and a diluent, which reconstituted formulation has been prepared from a lyophilized mixture of a protein and a lyoprotectant, wherein the protein concentration in the reconstituted formulation is about 2-40 times greater than the protein concentration in the mixture before lyophilization.
  • the invention provides a stable reconstituted formulation comprising an antibody in an amount of at least about 50 mg/mL and a diluent, which reconstituted formulation has been prepared from a lyophilized mixture of an antibody and a lyoprotectant, wherein the antibody concentration in the reconstituted formulation is about 2-40 times greater than the antibody concentration in the mixture before lyophilization.
  • the ratio of lyoprotectantrprotein in the lyophilized formulation ofthe preceding paragraphs depends, for example, on both the protein and lyoprotectant of choice, as well as the desired protein concentration and isotonicity ofthe reconstituted formulation.
  • the ratio may, for example, be about 100-1500 mole trehalose or sucrose: 1 mole antibody.
  • the pre-lyophilized formulation ofthe protein and lyoprotectant will further include a buffer which provides the formulation at a suitable pH, depending on the protein in the formulation.
  • a buffer which provides the formulation at a suitable pH, depending on the protein in the formulation.
  • the formulation may further include a surfactant (e.g. a polysorbate) in that it has been observed herein that this can reduce aggregation ofthe reconstituted protein and/or reduce the formation of particulates in the reconstituted formulation.
  • a surfactant e.g. a polysorbate
  • the surfactant can be added to the pre-lyophilized formulation, the lyophilized formulation and/or the reconstituted formulation (but preferably the pre-lyophilized formulation) as desired.
  • the invention further provides a method for preparing a stable isotonic reconstituted formulation comprising reconstituting a lyophilized mixture ofa protein and a lyoprotectant in a diluent such that the protein concentration in the reconstituted formulation is at least 50 mg/mL, wherein the protein concentration in the reconstituted formulation is about 2-40 times greater than the protein concentration in the mixture before lyophilization.
  • the invention provides a method for preparing a formulation comprising the steps of: (a) lyophilizing a mixture of a protein and a lyoprotectant; and (b) reconstituting the lyophilized mixture of step (a) in a diluent such that the reconstituted formulation is isotonic and stable and has a protein concentration of at least about 50 mg/mL.
  • the protein concentration in the reconstituted formulation may be from about 80 mg/mL to about 300 mg/mL.
  • the protein concentration in the reconstituted formulation is about 2-40 times greater than the protein concentration in the mixture before lyophilization.
  • An article of manufacture is also provided herein which comprises: (a) a container which holds a lyophilized mixture of a protein and a lyoprotectant; and (b) instructions for reconstituting the lyophilized mixture with a diluent to a protein concentration in the reconstituted formulation of at least about 50 mg/mL.
  • the article of manufacture may further comprise a second container which holds a diluent (e.g. bacteriostatic water for injection (BWFI) comprising an aromatic alcohol).
  • BWFI bacteriostatic water for injection
  • the invention further provides a method for treating a mammal comprising administering a therapeutically effective amount of a reconstituted formulation disclosed herein to a mammal, wherein the mammal has a disorder requiring treatment with the protein in the formulation.
  • the formulation may be administered subcutaneously.
  • anti-HER2 antibody pre-lyophilized formulation as discovered in the experiments detailed below was found to comprise anti-HER2 in amount from about 5-40 mg/mL (e.g. 20-30 mg/mL) and sucrose or trehalose in an amount from about 10-100 mM (e.g. 40-80 mM), a buffer (e.g. histidine, pH 6 or succinate, pH 5) and a surfactant (e.g. a polysorbate).
  • the lyophilized formulation was found to be stable at 40 ° C for at least 3 months and stable at 30° C for at least 6 months.
  • This anti-HER2 formulation can be reconstituted with a diluent to generate a formulation suitable for intravenous administration comprising anti-HER2 in an amount from about 10-30 mg/mL which is stable at 2-8° C for at least about 30 days. Where higher concentrations ofthe anti-HER2 antibody are desired (for example where subcutaneous delivery ofthe antibody is the intended mode of administration to the patient).
  • the lyophilized formulation may be reconstituted to yield a stable reconstituted formulation having a protein concentration of 50 mg/mL or more.
  • anti-IgE antibody pre-lyophilized formulation discovered herein has anti-IgE in amount from about 5-40 mg/mL (e.g. 20-30 mg/mL) and sucrose or trehalose in an amount from about 60-300 M (e.g.
  • the lyophilized anti- IgE formulation is stable at 30° C for at least 1 year.
  • This formulation can be reconstituted to yield a formulation comprising anti-IgE in an amount from about 15-45 mg/mL (e.g. 15-25 mg/mL) suitable for intravenous administration which is stable at 2-8° C for at least 1 year.
  • the lyophilized formulation can be reconstituted in order to generate a stable formulation having an anti-IgE concentration of ⁇ 50 mg/mL.
  • Figure 1 shows the effect of reconstitution volume on the stability of lyophilized rhuMAb HER2.
  • the lyophilized formulation was prepared from a pre-lyophilization formulation comprising 25 mg/mL protein, 60 mM trehalose. 5 mM sodium succinate, pH 5.0, and 0.01% Tween 20TM. The lyophilized cake was incubated at 40° C and then reconstituted with 4.0 (o) or 20.0 mL (•) of BWFI. The fraction of intact protein in the reconstituted formulation was measured by native size exclusion chromatography and defined as the peak area ofthe native protein relative to the total peak area including aggregates.
  • Figure 2 illustrates the effect of trehalose concentration on the stability of lyophilized rhuMAb HER2.
  • the protein was lyophilized at 25 mg/mL in 5 mM sodium succinate, pH 5.0 (circles) or 5 mM histidine, pH 6.0 (squares) and trehalose concentrations ranging from 60 mM (360 molar ratio) to 200 mM ( 1200 molar ratio).
  • the lyophilized protein was incubated at 40° C for either 30 days (closed symbols) or 91 days (open symbols).
  • the amount of intact protein was measured after reconstitution ofthe lyophilized protein with 20 mL BWFI.
  • Figure 3 demonstrates the effect of trehalose concentration on the long term stability of lyophilized rhuMAb HER2 stored at 40° C.
  • the protein was lyophilized at either 25 mg/mL in 5 mM sodium succinate, pH 5.0, 0.01% Tween 20TM. and 60 mM trehalose ( ⁇ ) or 5 mM histidine, pH 6.0. 0.01% Tween 20TM, and 60 mM trehalose (D) or21 mg/mL in 10 mM sodium succinate, pH 5.0, 0.2% Tween 20TM and 250 mM trehalose (•).
  • the lyophilized protein was incubated at 40° C and then reconstituted with 20 mL of BWFI. The amount of intact protein was measured after reconstitution.
  • Figure 4 shows the stability of rhuMAb HER2 lyophilized in 38.4 mM mannitol (7 mg/mL), 20.4 mM sucrose (7 mg/mL), 5 mM histidine, pH 6.0, 0.01% Tween 20TM.
  • the lyophilized protein was incubated at 40° C and then reconstituted with either 4.0 mL (o) or 20 mL (• ) of BWFI. The amount of intact protein was measured after reconstitution.
  • Figure 5 demonstrates stability of reconstituted rhuMAb HER2 lyophilized in 5 mM sodium succinate, pH 5.0, 60 mM trehalose, 0.01% Tween 20TM.
  • Samples were reconstituted with either 4.0 mL (squares) or 20.0 mL (circles) of BWFI (20 mL:0.9% benzyl alcohol; 4 mL:l.l% benzyl alcohol) and then stored at 5°C (solid symbols) or 25° C (open symbols).
  • the % native protein was defined as the peak area of the native (not degraded) protein relative to the total peak area as measured by cation exchange chromatography.
  • Figure 6 shows stability of reconstituted rhuMAb HER2 lyophilized in 5 mM histidine, pH 6.0, 60 mM trehalose, 0.01% Tween 20.
  • Samples were reconstituted with either 4.0 mL (squares) or 20.0 mL (circles) of BWFI (20 mL:0.9% benzyl alcohol; 4 mL:l.l% benzyl alcohol) and then stored at 5°C (solid symbols) or 25 °C (open symbols).
  • the % native protein was defined as the peak area ofthe native (not degraded) protein relative to the total peak area as measured by cation exchange chromatography.
  • Figure 7 reveals stability of reconstituted rhuMAb HER2 lyophilized in 5 mM histidine, pH 6.0, 38.4 mM mannitol, 20.4 mM sucrose, 0.01% Tween 20.
  • Samples were reconstituted with either 4.0 mL (squares) or 20.0 mL (circles) of BWFI (20 mL:0.9% benzyl alcohol; 4 mL: 1.1 % benzyl alcohol) and then stored at 5° C (solid symbols) or 25 ° C (open symbols).
  • the % native protein was defined as the peak area ofthe native (not degraded) protein relative to the total peak area as measured by cation exchange chromatography.
  • Figure 8 shows stability of reconstituted rhuMAb HER2 lyophilized in 10 mM sodium succinate, pH
  • the buffers were: potassium phosphate pH 7.0 (o); sodium phosphate pH 7.0 (D); histidine pH 7.0 (o); sodium succinate pH 6.5 (•); sodium succinate pH 6.0 ( ⁇ ); sodium succinate pH 5.5 ( ⁇ ); and sodium succinate pH 5.0 (*).
  • Figure 10 depicts aggregation of rhuMAb E25 lyophilized in 5 mM histidine buffer at both pH 6 and pH 7 and assayed following storage as follows.
  • the buffer was at: pH 6.0 stored at 2-8° C (o); pH 6 stored at 25° C (D); pH 6 stored at 40° C (0); pH 7 stored at 2-8° C (•); pH 7 stored at 25° C ( ⁇ ); and pH 7 stored at 40° C
  • Figure 11 illustrates aggregation of 5 mg/mL rhuMAb E25 formulated into 10 mM sodium succinate at pH 5.0 with lyoprotectant added at a concentration of 275 mM (isotonic).
  • the lyoprotectants were: control, no lyoprotectant (o); mannitol (D); lactose (0); maltose (•); trehalose ( ⁇ ): and sucrose ( ⁇ ). Samples were lyophilized and assayed at time zero and after 4 weeks, 8 weeks, and 52 weeks of storage at 2-8° C.
  • Figure 12 shows aggregation of 5 mg/mL rhuMAb E25 formulated into 10 mM sodium succinate at pH 5.0 with lyoprotectant added at a concentration of 275 mM (isotonic).
  • the lyoprotectants were: control, no lyoprotectant (o); mannitol (D); lactose (0); maltose (•); trehalose ( ⁇ ); and sucrose ( ⁇ ). Samples were lyophilized and assayed at time zero and after 4 weeks. 8 weeks, and 52 weeks of storage at 40° C.
  • Figure 13 depicts hydrophobic interaction chromatography of 20 mg/mL rhuMAb E25 lyophilized in histidine buffer at pH 6 with an isotonic concentration (Le. 275 mM) of lactose stored for 24 weeks at 2-8, 25 or 40° C and reconstituted to 20 mg/mL.
  • Figure 14 shows hydrophobic interaction chromatography of 20 mg/mL rhuMAb E25 lyophilized in histidine buffer at pH 6 stored for 24 weeks at 2-8, 25 or 40° C and reconstituted to 20 mg/mL.
  • Figure 15 illustrates hydrophobic interaction chromatography of 20 mg/mL rhuMAb E25 lyophilized in histidine buffer at pH 6 with an isotonic concentration (Le. 275 mM) of sucrose and stored for 24 weeks at 2-8, 25 or 40° C and reconstituted to 20 mg/mL.
  • Figure 16 illustrates the effect of sugar concentration on rhuMAb E25 formulated at 20 mg/mL in 5 mM histidine at pH 6.0.
  • Sucrose (•) and trehalose (D) were added to the formulation at molar ratios ranging from 0 to 2010 (isotonic) (see Table 1 below). Samples were lyophilized and assayed after 12 weeks of storage at 50° C.
  • Figure 17 reveals aggregation of rhuMAb E25 formulated at 25 mg/mL into 5 mM histidine at pH 6 with 85 mM sucrose (o); 85 mM trehalose (D): 161 mM sucrose ( ⁇ ) or 161 mM trehalose (*).
  • Samples were lyophilized and stored at 2-8° C followed by reconstitution with 0.9% benzyl alcohol to 100 mg/mL antibody in 20 mM histidine at pH 6 with isotonic (340 mM) and hypertonic (644 mM) sugar concentration.
  • Figure 18 shows aggregation of rhuMAb E25 formulated at 25 mg/mL into 5 mM histidine at pH 6 with 85 mM sucrose (o); 85 mM trehalose (D); 161 mM sucrose ( ⁇ ) or 161 mM trehalose (*). Samples were lyophilized and stored at 30° C followed by reconstitution with 0.9% benzyl alcohol to 100 mg/mL antibody in 20 mM histidine at pH 6 with isotonic (340 mM) and hypertonic (644 mM) sugar concentration.
  • Figure 19 illustrates aggregation of rhuMAb E25 formulated at 25 mg/mL into 5 mM histidine at pH
  • protein is meant a sequence of amino acids for which the chain length is sufficient to produce the higher levels of tertiary and/or quaternary structure. This is to distinguish from “peptides” or other small molecular weight drugs that do not have such structure.
  • the protein herein will have a molecular weight of at least about 15-20 kD, preferably at least about 20 kD.
  • proteins encompassed within the definition herein include mammalian proteins, such as, e.g., growth hormone, including human growth hormone and bovine growth hormone; growth hormone releasing factor; parathyroid hormone; thyroid stimulating hormone; lipoproteins; ⁇ -1-antitrypsin; insulin A-chain; insulin B-chain; proinsulin; follicle stimulating hormone; calcitonin; luteinizing hormone; glucagon; clotting factors such as factor VIIIC, factor LX, tissue factor, and von Willebrands factor; anti-clotting factors such as Protein C; atrial natriuretic factor; lung surfactant; a plasminogen activator, such as urokinase or tissue-type plasminogen activator
  • t-PA bombazine
  • thrombin tumor necrosis factor- ⁇ and - ⁇
  • enkephalinase RANTES (regulated on activation normally T-cell expressed and secreted); human macrophage inflammatory protein (MIP-1- ⁇ ); serum albumin such as human serum albumin; mullerian-inhibiting substance; relaxin A-chain; relaxin B-chain; prorelaxin; mouse gonadotropin-associated peptide; DNase; inhibin; activin; vascular endothelial growth factor (VEGF); receptors for hormones or growth factors; an integrin; protein A or D; rheumatoid factors; a neurotrophic factor such as bone-derived neurotrophic factor (BDNF), neurotrophin-3, -4, -5, or -6 (NT-3, NT-4, NT-5, or NT-6), or a nerve growth factor such as NGF- ⁇ ; platelet-derived growth factor (PDGF); fibroblast growth factor such as aFGF and b
  • Essentially pure protein means a composition comprising at least about 90% by weight ofthe protein, based on total weight ofthe composition, preferably at least about 95% by weight.
  • Essentially homogeneous protein means a composition comprising at least about 99% by weight of protein, based on total weight ofthe composition.
  • the protein is an antibody. The antibody may bind to any of the above ⁇ mentioned molecules, for example.
  • Exemplary molecular targets for antibodies encompassed by the present invention include CD proteins such as CD3, CD4, CD8, CD19, CD20 and CD34; members ofthe HER receptor family such as the EGF receptor, HER2, HER3 or HER4 receptor; cell adhesion molecules such as LFA-1, Mol, ⁇ l50,95, VLA-4, ICAM-l. VCAM and ⁇ v/ ⁇ 3 integrin including either ⁇ or ⁇ subunits thereof (e.g. anti-CDl la, anti-CD 18 or anti-CDl lb antibodies); growth factors such as VEGF; IgE; blood group antigens; flk2/flt3 receptor; obesity (OB) receptor; protein C etc.
  • CD proteins such as CD3, CD4, CD8, CD19, CD20 and CD34
  • members ofthe HER receptor family such as the EGF receptor, HER2, HER3 or HER4 receptor
  • cell adhesion molecules such as LFA-1, Mol, ⁇ l50,95, VLA-4, ICAM-l
  • antibody is used in the broadest sense and specifically covers monoclonal antibodies (including full length antibodies which have an immunoglobulin Fc region), antibody compositions with polyepitopic specificity, bispecific antibodies, diabodies, and single-chain molecules, as well as antibody fragments (e.g., Fab, F(ab');,. and Fv).
  • the term "monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by the hybridoma culture, uncontaminated by other immunoglobulins.
  • the modifier "monoclonal” indicates the character ofthe antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
  • the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al.. Nature, 256: 495 (1975), or may be made by recombinant DNA methods (see, e.g., U.S. Patent No. 4.816,567).
  • the "monoclonal antibodies” may also be isolated from phage antibody libraries using the techniques described in Clackson et ai, Nature, 352:624-628 (1991) and Marks et ai, J. Mol. Biol., 222:581-597 (1991), for example.
  • the monoclonal antibodies herein specifically include "chimeric" antibodies (immunoglobulins) in which a portion ofthe heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder ofthe chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Patent No. 4,816,567; Morrison et ai, Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)).
  • chimeric antibodies immunoglobulins in which a portion ofthe heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder ofthe chain(s) is identical with or homologous to corresponding sequences
  • Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab') 2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin.
  • humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementarity determining region (CDR) ofthe recipient are replaced by residues from a CDR of a non ⁇ human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity, and capacity.
  • CDR complementarity determining region
  • humanized antibodies may comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications are made to further refine and optimize antibody performance.
  • the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all ofthe CDR regions correspond to those of a non-human immunoglobulin and all or substantially all ofthe FR regions are those ofa human immunoglobulin sequence.
  • the humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
  • Fc immunoglobulin constant region
  • the humanized antibody includes a PrimatizedTM antibody wherein the antigen-binding region of the antibody is derived from an antibody produced by immunizing macaque monkeys with the antigen of interest.
  • a “stable” formulation is one in which the protein therein essentially retains its physical and chemical stability and integrity upon storage.
  • Various analytical techniques for measuring protein stability are available in the art and are reviewed in Peptide and Protein Drug Delivery, 247-301, Vincent Lee Ed., Marcel Dekker, Inc., New York, New York, Pubs. ( 1991 ) and Jones, A. Adv. Drug Delivery Rev. 10: 9-90 ( 1993).
  • Stability can be measured at a selected temperature for a selected time period. For rapid screening, the formulation may be kept at 40 ' C for 2 weeks to 1 month, at which time stability is measured.
  • the formulation should be stable at 30 ° C or 40 ° C for at least 1 month and/or stable at 2-8 ° C for at least 2 years.
  • the formulation should be stable for at least 2 years at 30 ° C and/or stable at 40 ' C for at least 6 months.
  • the extent of aggregation following lyophilization and storage can be used as an indicator of protein stability (see Examples herein).
  • a "stable" formulation may be one wherein less than about 10% and preferably less than about 5% of the protein is present as an aggregate in the formulation. In other embodiments, any increase in aggregate formation following lyophilization and storage ofthe lyophilized formulation can be determined.
  • a “stable" lyophilized formulation may be one wherein the increase in aggregate in the lyophilized formulation is less than about 5% and preferably less than about 3%, when the lyophilized formulation is stored at 2-8° C for at least one year.
  • stability ofthe protein formulation may be measured using a biological activity assay (see, e.g.. Example 2 below).
  • a "reconstituted" formulation is one which has been prepared by dissolving a lyophilized protein formulation in a diluent such that the protein is dispersed in the reconstituted formulation.
  • the reconstituted formulation in suitable for administration (e.g. parenteral administration) to a patient to be treated with the protein of interest and, in certain embodiments ofthe invention, may be one which is suitable for subcutaneous administration.
  • isotonic is meant that the formulation of interest has essentially the same osmotic pressure as human blood. Isotonic formulations will generally have an osmotic pressure from about 250 to 350mOsm. Isotonicity can be measured using a vapor pressure or ice-freezing type osmometer, for example.
  • a “lyoprotectant” is a molecule which, when combined with a protein of interest, significantly prevents or reduces chemical and/or physical instability of the protein upon lyophilization and subsequent storage.
  • exemplary lyoprotectants include sugars such as sucrose or trehalose; an amino acid such as monosodium glutamate or histidine; a methylamine such as betaine; a lyotropic salt such as magnesium sulfate: a polyol such as trihydric or higher sugar alcohols, e.g.
  • the preferred lyoprotectant is a non-reducing sugar, such as trehalose or sucrose.
  • the lyoprotectant is added to the pre-lyophilized formulation in a "lyoprotecting amount" which means that, following lyophilization ofthe protein in the presence ofthe lyoprotecting amount ofthe lyoprotectant, the protein essentially retains its physical and chemical stability and integrity upon lyophilization and storage.
  • the "diluent" of interest herein is one which is pharmaceutically acceptable (safe and non-toxic for administration to a human) and is useful for the preparation of a reconstituted formulation.
  • exemplary diluents include sterile water, bacteriostatic water for injection (BWFI), a pH buffered solution (e.g. phosphate-buffered saline), sterile saline solution, Ringer's solution or dextrose solution.
  • a "preservative" is a compound which can be added to the diluent to essentially reduce bacterial action in the reconstituted formulation, thus facilitating the production ofa multi-use reconstituted formulation, for example.
  • potential preservatives include octadecyldimethylbenzyl ammonium chloride, hexamethonium chloride, benzalkonium chloride (a mixture of alkylbenzyldimethylammonium chlorides in which the alkyl groups are long-chain compounds), and benzethonium chloride.
  • preservatives include aromatic alcohols such as phenol, butyl and benzyl alcohol, alkyl parabens such as methyl or propyl paraben, catechoi, resorcinol, cyclohexanol. 3-pentanol, and m-cresol.
  • aromatic alcohols such as phenol, butyl and benzyl alcohol
  • alkyl parabens such as methyl or propyl paraben
  • catechoi resorcinol
  • cyclohexanol cyclohexanol. 3-pentanol, and m-cresol.
  • the most preferred preservative herein is benzyl alcohol.
  • a “bulking agent” is a compound which adds mass to the lyophilized mixture and contributes to the physical structure ofthe lyophilized cake (e.g. facilitates the production of an essentially uniform lyophilized cake which maintains an open pore structure).
  • Exemplary bulking agents include mannitol, glycine, polyethylene glycol and xorbitol.
  • Treatment refers to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include those already with the disorder as well as those in which the disorder is to be prevented.
  • “Mammal” for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, cows, etc.
  • the mammal is human.
  • a “disorder” is any condition that would benefit from treatment with the protein. This includes chronic and acute disorders or diseases including those pathological conditions which predispose the mammal to the disorder in question. Non-limiting examples of disorders to be treated herein include carcinomas and allergies. II. Modes for Carrying out the Invention A. Protein Preparation
  • the protein to be formulated is prepared using techniques which are well established in the art including synthetic techniques (such as recombinant techniques and peptide synthesis or a combination of these techniques) or may be isolated from an endogenous source ofthe protein.
  • the protein of choice is an antibody. Techniques for the production of antibodies follow. (i) Polyclonal antibodies.
  • a protein that is immunogenic in the species to be immunized e.g., keyhole limpet hemocyanin, serum albumin, bovine thy
  • Animals are immunized against the antigen, immunogenic conjugates, or derivatives by combining 1 mg or 1 ⁇ g ofthe peptide or conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant.
  • the animals are boosted with 1/5 to 1/10 the original amount of peptide or conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites.
  • the animals are bled and the serum is assayed for antibody titer. Animals are boosted until the titer plateaus.
  • the animal is boosted with the conjugate ofthe same antigen, but conjugated to a different protein and/or through a different cross-linking reagent.
  • Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are suitably used to enhance the immune response. (ii) Monoclonal antibodies.
  • Monoclonal antibodies are obtained from a population of substantially homogeneous antibodies, Le., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Thus, the modifier "monoclonal" indicates the character ofthe antibody as not being a mixture of discrete antibodies.
  • the monoclonal antibodies may be made using the hybridoma method first described by Kohler et al., Nature, 256:495 (1975), or may be made by recombinant DNA methods (U.S. Patent No. 4,816,567).
  • a mouse or other appropriate host animal such as a hamster
  • lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization.
  • lymphocytes may be immunized in vitro. Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, pp.59-103 (Academic Press, 1986)).
  • the hybridoma cells thus prepared are seeded and grown in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival ofthe unfused, parental myeloma cells.
  • a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival ofthe unfused, parental myeloma cells.
  • the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase
  • HGPRT the culture medium for the hybridomas typically will include hypoxanthine. aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells.
  • hypoxanthine aminopterin
  • HAT medium thymidine
  • Preferred myeloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium.
  • preferred myeloma cell lines are murine myeloma lines, such as those derived from MOPC-21 and MPC-11 mouse tumors available from the Salk Institute Cell Distribution Center. San Diego, California USA. and SP-2 cells available from tlie American Type Culture Collection. Rockville, Maryland USA.
  • Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, J. Immunol., 133:3001 (1984); Brodeur ..f al, Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)).
  • Culture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against the antigen.
  • the binding specificity of monoclonal antibodies produced by hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA).
  • RIA radioimmunoassay
  • ELISA enzyme-linked immunoabsorbent assay
  • the binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson et al.. Anal. Biochem., 107:220 (1980).
  • the clones may be subcloned by limiting dilution procedures and grown by standard methods (Goding, Monoclonal Antibodies: Principles and Practice, pp.59-103 (Academic Press, 1986)).
  • Suitable culture media for this purpose include, for example, D-MEM or RPMI- 1640 medium.
  • the hybridoma cells may be grown in vivo as ascites tumors in an animal.
  • the monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
  • DNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies).
  • the hybridoma cells serve as a preferred source of such D A.
  • the DNA may be placed into expression vectors, which are then transfected into host cells such as E. coli cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells.
  • host cells such as E. coli cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein.
  • Review articles on recombinant expression in bacteria of DNA encoding the antibody include Skerra et al., Curr. Opinion in Immunol, 5:256-262 (1993) and Pluckthun, Immunol. Revs., 130:151-188 (1992).
  • antibodies can be isolated from antibody phage libraries generated using the techniques described in McCafferty et al, Nature, 348:552-554 (1990). Clackson et al. Nature, 352:624-628 (1991) and Marks et al, J. Mol. Biol, 222:581-597 (1991) describe the isolation of murine and human antibodies, respectively, using phage libraries. Subsequent publications describe the production of high affinity (nM range) human antibodies by chain shuffling (Marks et al.
  • the DNA also may be modified, for example, by substituting the coding sequence for human heavy- and light-chain constant domains in place ofthe homologous murine sequences (U.S. Patent No. 4,816,567; Morrison, etal, Proc. Natl Acad. Sci. USA, 81 :6851 (1984)), or by covalently joining to the immunoglobulin coding sequence all or pan ofthe coding sequence for a non-immunoglobulin polypeptide.
  • non-immunoglobulin polypeptides are substituted for the constant domains of an antibody, or they are substituted for the variable domams of one antigen-combining site of an antibody to create a chimeric bivalent antibody comprising one antigen-combining site having specificity for an antigen and another antigen-combining site having specificity for a different antigen.
  • Chimeric or hybrid antibodies also may be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents.
  • immunotoxins may be constructed using a disulfide-exchange reaction or by forming a thioether bond.
  • suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate.
  • a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non- human amino acid residues are often referred to as "import" residues, which are typically taken from an "import” variable domain. Humanization can be essentially performed following the method of Winter and co-workers (Jones et al, Nature, 321:522-525 (1986); Riechmann et al. Nature, 332:323-327 (1988); Verhoeyen et al, Science, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences ofa human antibody.
  • humanized antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species.
  • humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.
  • variable domains both light and heavy
  • the choice of human variable domains, both light and heavy, to be used in making the humanized antibodies is very important to reduce antigenicity.
  • the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable- domain sequences.
  • the human sequence which is closest to that ofthe rodent is then accepted as the human framework (FR) for the humanized antibody (Sims et al. , J. Immunol. , 151 :2296 ( 1993 ); Chothia et al. , J. Mol. Biol, 196:901 (1987)).
  • Another method uses a particular framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains.
  • the same framework may be used for several different humanized antibodies (Carter et al, Proc. Natl. Acad. Sci. USA, 89:4285 (1992); Presta et al, J. Immnol, 151:2623 (1993)).
  • humanized antibodies are prepared by a process of analysis ofthe parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences.
  • Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art.
  • Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis ofthe likely role ofthe residues in the functioning ofthe candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability ofthe candidate immunoglobulin to bind its antigen.
  • FR residues can be selected and combined from the recipient and import sequences so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved.
  • the CDR residues are directly and most substantially involved in influencing antigen binding.
  • transgenic animals e.g., mice
  • transgenic animals e.g., mice
  • J H antibody heavy-chain joining region
  • Bispecific antibodies are antibodies that have binding specificities for at least two different epitopes. Such antibodies can be derived from full length antibodies or antibody fragments (e.g. F(ab') 2 bispecific antibodies).
  • bispecific antibodies are known in the art. Traditional production of full length bispecific antibodies is based on the coexpression of two immunoglobulin heavy chain-light chain pairs, where the two chains have different specificities (Millstein et al. Nature, 305:537-539 (1983)). Because ofthe random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of 10 different antibody molecules, of which only one has the correct bispecific structure. Purification ofthe correct molecule, which is usually done by affinity chromatography steps, is rather cumbersome, and the product yields are low. Similar procedures are disclosed in WO 93/08829 and in Traunecker et al, EMBO J. , 10:3655-
  • antibody variable domains with the desired binding specificities are fused to immunoglobulin constant domain sequences.
  • the fusion preferably is with an immunoglobulin heavy chain constant domain, comprising at least part ofthe hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CHI) containing the site necessary for light chain binding, present in at least one ofthe fusions.
  • DNAs encoding the immunoglobulin heavy chain fusions and, if desired, the immunoglobulin light chain are inserted into separate expression vectors, and are co ⁇ transfected into a suitable host organism.
  • the bispecific antibodies are composed of a hybrid immunoglobulin heavy chain with a first binding specificity in one arm, and a hybrid immunoglobulin heavy chain-light chain pair (providing a second binding specificity) in the other arm. It was found that this asymmetric structure facilitates the separation ofthe desired bispecific compound from unwanted immunoglobulin chain combinations, as the presence of an immunoglobulin light chain in only one half of the bispecific molecule provides for a facile way of separation. This approach is disclosed in WO 94/04690 published March 3, 1994. For further details of generating bispecific antibodies see, for example, Suresh et al. Methods in Enzymoiogy, 121:210 (1986).
  • Bispecific antibodies include cross-linked or "heteroconjugate" antibodies.
  • one ofthe antibodies in the heteroconjugate can be coupled to avidin, the other to biotin.
  • Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (US Patent No. 4,676,980), and for treatment of HIV infection (WO 91/00360. WO 92/200373).
  • Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents are well known in the art. and are disclosed in US Patent No. 4,676,980, along with a number of cross-linking techniques.
  • bispecific antibodies from antibody fragments
  • the following techniques can also be used for the production of bivalent antibody fragments which are not necessarily bispecific.
  • Fab' fragments recovered from E. coli can be chemically coupled in vitro to form bivalent antibodies. See, Shalaby et al, J. Exp. Med., 175:217-225 (1992).
  • bivalent heterodimers have been produced using leucine zippers.
  • the leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion.
  • the antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers.
  • the "diabody" technology described by Hollinger et al, Proc. Natl. Acad. Sci.
  • the fragments comprise a heavy-chain variable domain (V H ) connected to a light-chain variable domain (V L ) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V tension and V L domains of one fragment are forced to pair with the complementary V L and V H domains of another fragment, thereby forming two antigen-binding sites.
  • V H heavy-chain variable domain
  • V L light-chain variable domain
  • Another strategy for making bispecific/bivalent antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See Gruber et al, J. Immunol, 152:5368 (1994).
  • a "pre-lyophilized formulation” is produced.
  • the amount of protein present in the pre-lyophilized formulation is determined taking into account the desired dose volumes, mode(s) of administration etc.
  • the protein of choice is an intact antibody (such as an anti-IgE or anti-HER2 antibody)
  • from about 2 mg/mL to about 50 mg/mL, preferably from about 5 mg mL to about 40 mg/mL and most preferably from about 20-30 mg/mL is an exemplary starting protein concentration.
  • the protein is generally present in solution.
  • the protein may be present in a pH-buffered solution at a pH from about 4-8. and preferably from about 5-7.
  • Exemplary buffers include histidine, phosphate, Tris. citrate, succinate and other organic acids.
  • the buffer concentration can be from about 1 mM to about 20 mM, or from about 3 mM to about 15 mM, depending, for example, on the buffer and the desired isotonicity ofthe formulation (e.g. ofthe reconstituted formulation).
  • the preferred buffer is histidine in that, as demonstrated below, this can have lyoprotective properties. Succinate was shown to be another useful buffer.
  • the lyoprotectant is added to the pre-lyophilized formulation.
  • the lyoprotectant is a non-reducing sugar such as sucrose or trehalose.
  • the amount of lyoprotectant in the pre- lyophilized formulation is generally such that, upon reconstitution, the resulting formulation will be isotonic. However, hypertonic reconstituted formulations may also be suitable. In addition, the amount of lyoprotectant must not be too low such that an unacceptable amount of degradation aggregation ofthe protein occurs upon lyophilization.
  • lyoprotectant concentrations in the pre-lyophilized formulation are from about 10 mM to about 400 mM, and preferably from about 30 mM to about 300 mM, and most preferably from about 50 mM to about 100 mM.
  • the ratio of protein to lyoprotectant is selected for each protein and lyoprotectant combination.
  • the molar ratio of lyoprotectant to antibody may be from about 100 to about 1500 moles lyoprotectant to 1 mole antibody, and preferably from about 200 to about 1000 moles of lyoprotectant to 1 mole antibody, for example from about 200 to about 600 moles of lyoprotectant to 1 mole antibody.
  • a surfactant to the pre-lyophilized formulation.
  • the surfactant may be added to the lyophilized formulation and/or the reconstituted formulation.
  • exemplary surfactants include nonionic surfactants such as polysorbates (e.g. polysorbates 20 or 80); poloxamers (e.g.
  • the amount of surfactant added is such that it reduces aggregation ofthe reconstituted protein and minimizes the formation of particulates after reconstitution.
  • the surfactant may be present in the pre-lyophilized formulation in an amount from about 0.001-0.5%, and preferably from about 0.005-0.05%.
  • a mixture ofthe lyoprotectant such as sucrose or trehalose
  • a bulking agent e.g. mannitol or glycine
  • the bulking agent may allow for the production ofa uniform lyophilized cake without excessive pockets therein etc.
  • Other pharmaceutically acceptable carriers, excipients or stabilizers such as those described in Remington's Pharmaceutical Sciences 16th edition. Osol. A. Ed. (1980) may be included in the pre-lyophilized formulation (and/or the lyophilized formulation and/or the reconstituted formulation) provided that they do not adversely affect the desired characteristics ofthe formulation.
  • Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed and include: additional buffering agents; preservatives; co-solvents; antioxidants including ascorbic acid and methionine: chelating agents such as EDTA; metal complexes (e.g. Zn-protein complexes); biodegradable polymers such as polyesters; and or salt-forming counterions such as sodium.
  • the formulation herein may also contain more than one protein as necessary for the pa ⁇ icular indication being treated, preferably those with complementary activities that do not adversely affect the other protein.
  • it may be desirable to provide two or more antibodies which bind to the HER2 receptor or IgE in a single formulation.
  • anti-HER2 and anti- VEGF antibodies may be combined in the one formulation.
  • Such proteins are suitably present in combination in amounts that are effective for the purpose intended.
  • the formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes, prior to. or following, lyophilization and reconstitution. Altematively, sterility ofthe entire mixture may be accomplished by autoclaving the ingredients, except for protein, at about 120°C for about 30 minutes, for example.
  • the formulation is lyophilized.
  • freeze-dryers are available for this purpose such as Hull50TM (Hull, USA) or GT20TM (Leybold-Heraeus. Germany) freeze-dryers. Freeze-drying is accomplished by freezing the formulation and subsequently subliming ice from the frozen content at a temperature suitable for primary drying. Under this condition, the product temperature is below the eutectic point or the collapse temperature ofthe formulation.
  • the shelf temperature for the primary drying will range from about -30 to 25° C (provided the product remains frozen during primary drying) at a suitable pressure, ranging typically from about 50 to 250mTorr.
  • the formulation, size and type ofthe container holding the sample (e.g., glass vial) and the volume of liquid will mainly dictate the time required for drying, which can range from a few hours to several days (e.g. 40-60hrs).
  • a secondary drying stage may be ca ⁇ ied out at about 0-40° C, depending primarily on the type and size of container and the type of protein employed. However, it was found herein that a secondary drying step may not be necessary.
  • the shelf temperature throughout the entire water removal phase of lyophilization may be from about 15-30° C (e.g. , about 20° C).
  • the time and pressure required for secondary drying will be that which produces a suitable lyophilized cake, dependent e.g., on the temperature and other parameters.
  • the secondary drying time is dictated by the desired residual moisture level in the product and typically takes at least about 5 hours (e.g. 10-15 hours).
  • the pressure may be the same as that employed during the primary drying step. Freeze-drying conditions can be varied depending on the formulation and vial size. In some instances, it may be desirable to lyophilize the protein formulation in the container in which reconstitution ofthe protein is to be carried out in order to avoid a transfer step.
  • the container in this instance may, for example, be a 3, 5, 10, 20, 50 or lOOcc vial.
  • lyophilization will result in a lyophilized formulation in which the moisture content thereof is less than about 5%, and preferably less than about 3%.
  • the lyophilized formulation may be reconstituted with a diluent such that the protein concentration in the reconstituted formulation is at least 50 mg/mL, for example from about 50 mg/mL to about 400 mg/mL, more preferably from about 80 mg/mL to about 300 mg/mL, and most preferably from about 90 mg/mL to about 150 mg/mL.
  • a diluent such that the protein concentration in the reconstituted formulation is at least 50 mg/mL, for example from about 50 mg/mL to about 400 mg/mL, more preferably from about 80 mg/mL to about 300 mg/mL, and most preferably from about 90 mg/mL to about 150 mg/mL.
  • Such high protein concentrations in the reconstituted formulation are considered to be particularly useful where subcutaneous delivery ofthe reconstituted formulation is intended.
  • the protein concentration in the reconstituted formulation is significantly higher than that in the pre-lyophilized formulation.
  • the protein concentration in the reconstituted formulation may be about 2-40 times, preferably 3-10 times and most preferably 3-6 times (e.g. at least three fold or at least four fold) that ofthe pre-lyophilized formulation.
  • Reconstitution generally takes place at a temperature of about 25° C to ensure complete hydration, although other temperatures may be employed as desired.
  • the time required for reconstitution will depend, e.g, on the type of diluent, amount of excipient(s) and protein.
  • Exemplary diluents include sterile water, bacteriostatic water for injection (BWFI), a pH buffered solution (e.g. phosphate-buffered saline), sterile saline solution, Ringer's solution or dextrose solution.
  • BWFI bacteriostatic water for injection
  • pH buffered solution e.g. phosphate-buffered saline
  • sterile saline solution e.g. phosphate-buffered saline
  • Ringer's solution or dextrose solution e.g. sterile saline
  • the diluent optionally contains a preservative. Exemplary preservatives have been described above
  • the amount of preservative employed is determined by assessing different preservative concentrations for compatibility with the protein and preservative efficacy testing. For example, if the preservative is an aromatic alcohol (such as benzyl alcohol), it can be present in an amount from about 0.1-2.0% and preferably from about 0.5-1.5%, but most preferably about 1.0-1.2%.
  • aromatic alcohol such as benzyl alcohol
  • the reconstituted formulation has less than 6000 particles per vial which are ⁇ 10 ⁇ m in size. D. Administration of the Reconstituted Formulation
  • the reconstituted formulation is administered to a mammal in need of treatment with the protein, preferably a human, in accord with known methods, such as intravenous administration as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal. intracerobrospinal, subcutaneous, uitra-articuIar. intrasynovial, intrathecal, oral, topical, or inhalation routes.
  • the reconstituted formulation is administered to the mammal by subcutaneous
  • the formulation may be injected using a syringe.
  • other devices for administration ofthe formulation are available such as injection devices (e.g. the Inject-easeTM and GenjectTM devices); injector pens (such as the GenPen TM; needleless devices (e.g. MediJectorTM and BioJectorTM); and subcutaneous patch delivery systems.
  • the appropriate dosage ("therapeutically effective amount") ofthe protein will depend, for example, on the condition to be treated, the severity and course ofthe condition, whether the protein is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the protein, the type of protein used, and the discretion ofthe attending physician.
  • the protein is suitably administered to the patient at one time or over a series of treatments and may be administered to the patient at any time from diagnosis onwards.
  • the protein may be administered as the sole treatment or in conjunction with other drugs or therapies useful in treating the condition in question.
  • the protein of choice is an antibody
  • from about 0.1-20 mg/kg is an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations.
  • other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques.
  • an anti-HER2 antibody In the case of an anti-HER2 antibody, a therapeutically effective amount of the antibody may be administered to treat or prevent cancer characterized by overexpression ofthe HER2 receptor. It is contemplated that a reconstituted formulation of the anti-HER2 antibody may be used to treat breast, ovarian, stomach, endometrial, salivary gland, lung, kidney, colon and/or bladder cancer. For example, the anti-HER2 antibody may be used to treat ductal carcinoma in situ (DCIS). Exemplary dosages of the anti-HER2 antibody are in the range 1-10 mg/kg by one or more separate administrations.
  • an anti-IgE formulation include the treatment or prophylaxis of IgE-mediated allergic diseases, parasitic infections, interstitial cystitis and asthma, for example.
  • a therapeutically effective amount e.g. from about 1-15 mg/kg
  • the anti-IgE antibody is administered to the patient.
  • an article of manufacture which contains the lyophilized formulation ofthe present invention and provides instructions for its reconstitution and/or use.
  • the article of manufacture comprises a container. Suitable containers include, for example, bottles. vials (e.g. dual chamber vials), syringes (such as dual chamber syringes) and test tubes.
  • the container may be formed from a variety of materials such as glass or plastic.
  • the container holds the lyophilized formulation and the label on, or associated with, the container may indicate directions for reconstitution and/or use.
  • the label may indicate that the lyophilized formulation is reconstituted to protein concentrations as described above.
  • the label may further indicate that the formulation is useful or intended for subcutaneous administration.
  • the container holding the formulation may be a multi-use vial, which allows for repeat administrations (e.g. from 2-6 administrations) ofthe reconstituted formulation.
  • the article of manufacture may further comprise a second container comprising a suitable diluent (e.g. BWFI). Upon mixing ofthe diluent and the lyophilized formulation, the final protein concentration in the reconstituted formulation will generally be at least 50 mg/mL.
  • the article of manufacture may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.
  • HER2 Overexpression ofthe HER2 proto-oncogene product has been associated with a variety of aggressive human malignancies.
  • the murine monoclonal antibody known as muMAb4D5 is directed against
  • HER2 the extracellular domain (ECD) of p 185 .
  • the muMAb4D5 molecule has been humanized in an attempt to improve its clinical efficacy by reducing immunogenicity and allowing it to support human effector functions (see WO 92/22653).
  • This example describes the development ofa lyophilized formulation comprising full length humanized antibody huMAb4D5-8 described in WO 92/22653.
  • excipients and buffers are initially screened by measuring the stability ofthe protein after lyophilization and reconstitution.
  • the lyophilized protein in each formulation is also subjected to accelerated stability studies to determine the potential stability ofthe protein over its shelf-life. These accelerated studies are usually performed at temperatures above the proposed storage conditions and the data are then used to estimate the activation energy for the degradation reactions assuming A ⁇ henius kinetics (Cleland et al, Critical Reviews in Therapeutic Drug Carrier Systems 10(4): 307-377 ( 1993)).
  • the activation energy is then used to calculate the expected shelf-life ofthe protein formulation at the proposed storage conditions.
  • rhuMAb HER2 humanized anti-HER2 antibody
  • 5°C proposed storage condition
  • 40° C accelerated stability condition
  • rhuMAb HER2 was observed to degrade by deamidation (30Asn of light chain) and isoaspartate formation via a cyclic imide intermediate, succinimide (102Asp of heavy chain).
  • the deamidation was minimized at pH 5.0 resulting in degradation primarily at the succinimide.
  • pH 6.0 slightly greater deamidation was observed in the liquid protein formulation.
  • the lyophilized formulations were therefore studied with: (a) 5 or 10 mM succinate buffer, pH 5.0 or (b) 5 or 10 mM histidine buffer, pH 6.0. Both buffers contained the surfactant, polysorbate 20 (Tween 20TM), which was employed to reduce the potential for aggregation ofthe reconstituted protein and minimize the formation of particulates after reconstitution. These buffers were used with and without various sugars. The protein was formulated in the buffer at 5.0.21.0 or 25.0 mg/mL. These formulations were then lyophilized and assessed for protein stability after 2 weeks at 5° C and 40° C. In the lyophilizer.
  • the vials were frozen at a shelf temperature of-55°C for approximately 5 hours followed by primary drying at a shelf temperature of 5° C and 150 mTo ⁇ for 30 hours, and drying to 1-2% residual moisture was achieved with secondary drying at a shelf temperature of 20°C for 10 hours.
  • the major degradation route for this protein upon lyophilization was aggregation, and therefore the protein stability was assessed by native size exclusion chromatography to measure the recovery of intact native protein (% intact protein in Table 2 below).
  • the 250 mM trehalose and 250 mM lactose formulations were assessed for long term stability. After 9 months at 40° C or 12 months at 5° C, there was no change in the % intact protein for the trehalose formulation. For the lactose formulation, the % intact protein remained constant (same as initial) after 3 months at 40° C or 6 months at25°C.
  • the trehalose formulation could be stored at controlled room temperature (15-30°C) for 2 years without a significant change in % intact protein.
  • the 10 mM histidine, pH 6.0 formulation with mannitol contained less aggregated protein after storage at 40°C for 2 weeks than the 10 mM succinate formulation. pH 5.0 with mannitol. This result may be related to some stabilizing effect contributed by histidine alone. After storage at 40° C for 2 weeks, there was, however, significant aggregation for histidine alone or histidine/mannitol formulations. The addition of sucrose at an equal mass to mannitol (10 mg/mL of each) in the histidine formulation stabilized the protein against aggregation for both storage conditions.
  • sucrose/glycine formulation provided the same stability as the sucrose/mannitol formulation.
  • the fraction of intact protein was measured by native size exclusion HPLC and the peak area ofthe native protein relative to the total peak area including aggregates (TSK3000 SW XL column, TosoHaas. with a flow rate of 1.0 mL/min; elution with phosphate buffered saline: detection at 214 and 280 nm).
  • the protein formulations were analyzed before lyophilization (liquid, 5° C) and after lyophilization and storage at 5° C or 40° C for 2 weeks.
  • Formulations containing 5 mg/mL protein were reconstituted with distilled water (20 mL, 5.0 mg/mL protein), and formulations containing 21 mg/mL protein were reconstituted with bacteriostatic water for injection (BWFI, 0.9%) benzyl alcohol; 20 mL, 20 mg/mL protein).
  • the lyophilization process may provide a method to allow concentration of the protein.
  • the protein is filled into vials at a volume (Vf) and then lyophilized.
  • the lyophilized protein is then reconstituted with a smaller volume (Vr) ofwater or preservative (e.g. BWFI) than the original volume (e.g. Vr
  • the solution is desirably isotonic.
  • the amount of trehalose in the lyophilized rhuMAb HER2 was reduced to produce an isotonic solution upon reconstitution to yield 100 mg/mL protein.
  • the stabilizing effect of trehalose was determined as a function of concentration for 5 mM sodium succinate, pH 5.0 and 5 mM histidine, pH 6.0 at 25.0 mg mL protein (Table 3). At trehalose concentrations from 60 to 200 mM. there was no significant aggregation after incubation ofthe lyophilized protein for 4 weeks at 40° C. These formulations were reconstituted with 20 mL of bacteriostatic water for injection (BWFI. USP, 0.9% benzyl alcohol).
  • the fraction of intact protein was measured by native size exclusion HPLC and defined as the peak area ofthe native protein relative to the total peak area including aggregates (TSK3000 SW XL column. TosoHaas, with a flow rate of 1.0 mL/min; elution with phosphate buffered saline; detection at 214 and 280 nm).
  • the protein formulations were analyzed before lyophilization (liquid, 5°C) and after lyophilization and storage at 5°C or40°C for 4 weeks.
  • Formulations were reconstituted with bacteriostatic water for injection (BWFI, USP, 0.9% w/w benzyl alcohol; 20 mL, 22 mg/mL protein).
  • BWFI bacteriostatic water for injection
  • b Reconstituted with 4 mL of BWFI (0.9% benzyl alcohol) to yield 100 mg/mL protein.
  • c Reconstituted with 4 mL of BWFI (1.1% benzyl alcohol) to yield 100 mg/mL protein.
  • Sample incubated for 2 weeks at 5°C or 40° C and then reconstituted with 20 mL of BWFI (0.9% benzyl alcohol) to yield 22 mg/mL protein.
  • rhuMAb HER2 is under investigation as a therapeutic for the treatment of breast cancer.
  • the protein is dosed to patients at 2 mg/kg on a weekly basis. Since the average weight of these patients is 65 kg, the average weekly dose is 130 mg of rhuMAb HER2.
  • the protein concentration for a weekly subcutaneous administration of rhuMAb HER2 may be approximately 100 mg/mL (130 mg average dose/1.5 mL). As mentioned above, this high protein concentration is difficult to manufacture and maintain in a stable form.
  • rhuMAb HER2 formulated in: (a) 5 mM sodium succinate, pH 5.0 or (b) 5 mM histidine, pH 6.0, was lyophilized at 25 mg/mL protein in 60 M trehalose, 0.01% Tween 20TM. The lyophilization was performed by filling 18 mL ofthe protein formulation into 50 cc vials. In the lyophilizer, the vials were frozen at a shelf temperature of -55°C for approximately 5 hours followed by primary drying at a shelf temperature of 5°C and 150 mTo ⁇ for 30 hours, and drying to 1-2% residual moisture was achieved with secondary drying at a shelf temperature of 20° C for 10 hours.
  • the lyophilized protein was then reconstituted with either 4 or 20 mL of BWFI (0.9 or 1.1% benzyl alcohol) to yield concentrated protein solutions:
  • the amount of aggregated protein appeared to increase slightly with decreasing trehalose concentration.
  • the stability ofthe lyophilized protein was not affected by the volume of reconstitution.
  • the amount of intact protein after incubation of the lyophilized protein at 40° C was the same for the 60 mM trehalose, 5 mM sodium succinate, pH 5.0, 0.01% Tween 20TM formulation reconstituted with either 4 or 20 mL of BWFI.
  • the 250 mM trehalose formulation was unchanged after 6 months at 40° C while both the 60 mM trehalose formulations were less stable.
  • the 60 mM trehalose formulations may then require refrigerated storage if the product specification at the end of its shelf-life is, for example, >98% intact protein by native size exclusion chromatography.
  • sucrose was also observed to prevent aggregation of rhuMAb HER2 after lyophilization and subsequent storage.
  • sucrose concentration must be reduced significantly.
  • the equal mass concentration of sucrose and mannitol (bulking agent) used in the screening studies prevented aggregation ofthe protein.
  • a lower concentration of sucrose and mannitol (equal mass concentrations) was chosen as a potential subcutaneous formulation of rhuMAb HER2.
  • the protein solution 25 mg/mL protein, 5 mM histidine, pH 6.0. 38.4 mM (7 mg/mL) mannitol.
  • the stability ofthe lyophilized rhuMAb HER2 formulations was dete ⁇ nined as a function of temperature.
  • These studies demonstrated that the trehalose and mannitol/sucrose formulations prevented degradation of the protein in the lyophilized state at high temperatures (40° C).
  • these experiments did not address the stability ofthe protein after reconstitution and storage.
  • the lyophilized rhuMAb HER2 formulations may be used for several administrations of the drug.
  • the vial configuration 450 mg rhuMAb HER2
  • the vial may be stored at least three weeks after reconstitution.
  • stability studies on the reconstituted rhuMAb HER2 formulations were performed at 5°C and 25° C.
  • the formulations were reconstituted to 100 mg/mL (4 mL BWFI).
  • the protein may be more susceptible to aggregation than the intravenous dosage form that was reconstituted to 22 mg/mL protein (20 mL BWFI).
  • the four rhuMAb HER2 formulations from the previous example were assessed for aggregation (loss of intact protein).
  • the samples were reconstituted with 4.0 or 20.0 mL of BWFI (1.1% or 0.9% benzyl alcohol), and then stored at 5°C or 25 °C.
  • rhuMAb HER2 the major degradation route for rhuMAb HER2 in aqueous solutions is deamidation or succinimide formation.
  • the loss of native protein due to deamidation or succinimide formation was assessed for the four reconstituted rhuMAb HER2 formulations.
  • Peak elution was monitored at 214 nm and 75 ⁇ g of protein was loaded for each analysis.
  • Multi-use formulations should pass preservative efficacy testing as described by the US Pharmacopeia (USP) for use in the United States.
  • USP US Pharmacopeia
  • the rhuMAb HER2 lyophilized formulation consisting of 25 mg/mL protein, 5 mM histidine, pH 6.0, 60 M trehalose, 0.01% Tween 20TM was reconstituted with 20 mL of benzyl alcohol at concentrations between 0.9 and 1.5% w/w. For concentrations at or above 1.3% w/w, the reconstituted solution became cloudy after overnight incubation at room temperature ( ⁇ 25 °C). Reconstitution with the standard BWFI solution (0.9% benzyl alcohol) resulted in a solution that did not consistently pass the preservative challenge tests.
  • a single step lyophilization cycle for the rhuMAb HER2 formulation was developed .
  • rhuMAb HER2 at 25 mg/mL, 60 mM trehalose, 5 mM histidine pH 6 and 0.01% polysorbate 20 was lyophilized at a shelf temperature of 20° C. and a pressure of 150 mTo ⁇ . After 47 hours. the residual moisture content ofthe lyophilized cake was less than 5%.
  • This lyophilization cycle is considered to be useful in that it simplifies the manufacturing process, by eliminating the secondary drying step.
  • IgE antibodies bind to specific high-affinity receptors on mast cells, leading to mast ceil degranulation and release of mediators, such as histamine, which produce symptoms associated with allergy.
  • mediators such as histamine
  • anti-IgE antibodies that block binding of IgE to its high-affinity receptor are of potential therapeutic value in the treatment of allergy.
  • These antibodies must also not bind to IgE once it is bound to the receptor because this would trigger histamine release.
  • This example describes the development of a lyophilized formulation comprising full length humanized anti-IgE antibody MaEl 1 described in Presta et al. J. Immunology, 151 : 2623-2632 (1993).
  • rhuMAb E25 recombinant humanized anti-IgE antibody MaE 11
  • Tween 20TM was used in the formulations described below.
  • Spectra/Por 7 dialysis membranes were purchased from Spectmm (Los Angeles, CA). All other reagents used in this study were obtained from commercial sources and were of analytical grade.
  • Formulation buffers and chromatography mobile phase were prepared by mixing the appropriate amount of buffer and salt with Milli-Q water in a volumetric flask.
  • E25 S Sepharose pool was dialyzed into formulation buffers as specified. Dialysis was accomplished by a minimum of 4 x 2L buffer exchanges over a 48 hour period at 2-8° C. Following dialysis, lyoprotectant was added at a isotonic concentration to some of the formulations as required. Protein concentration following dialysis was determined by UV spectroscopy using a molar absorptivity of 1.60. The dialyzed protein was diluted to the predetermined formulation concentration with an appropriate formulation buffer, sterile filtered using a 0.22 ⁇ m Millex-GV filter (Millipore) and dispensed into pre-washed and autoclaved glass vials.
  • Millex-GV filter Millex-GV filter
  • F(ab') 2 fragments of the E25 antibody were chromatographed using a TosoHaas Butyl-NPR column (3.5 x 4.6 mm) and a Hewlett Packard 1090L HPLC equipped with a diode array detector.
  • Elution buffer A was: 20 mM Tris, 2 M ammonium sulfate, 20% (v/v) glycerol, pH 8.0 while elution buffer B was: 20 mM Tris, 20% (v/v) glycerol, pH 8.0.
  • the column was equilibrated with 10% elution buffer B at a flow rate of 1.0 mL/min for a minimum of 20 minutes.
  • the sample load was 5 ⁇ g and protein was detected by monitoring the UV abso ⁇ tion at 214 nm using Turbochrom 3 data acquisition software (PE Nelson, Inc). Following injection ofthe sample, the column was maintained at 10% buffer B for 1 minute followed by a linear gradient of from 10% to 62% buffer B in 20 minutes. The column was washed with 100% buffer B for 5 minutes and re-equilibrated with 10% buffer B for a minimum of 20 minutes between successive sample injections.
  • IgE receptor binding inhibition assay (IE25:2) was ca ⁇ ied out as described in Presta et al, supra, on samples diluted to 20 ⁇ g/mL and 30 ⁇ g/mL in assay diluent (phosphate buffered saline, 0.5% BSA, 0.05% polysorbate 20. 0.01% Thimerosol). Each dilution was then assayed in triplicate and the results were multiplied by an appropriate dilution factor to yield an active concentration. The results from 6 assays were averaged. The assay measures the ability of rhuMAb E25 to competitively bind to
  • Particulate Assay Reconstituted vials of lyophilized rhuMAb E25 were pooled to achieve a volume of approximately 7 mL. A count ofthe number of particles of size ranging from 2 to 80 ⁇ m present in 1 mL of sample was determined using a Hiac/Royco model 8000 counter. The counter was first washed with 1 mL of sample three times followed by the measurement of 1 mL of sample in triplicate. The instrument determines the number of particles per mL that are equal to or greater than 10 ⁇ m and the number of particles per mL that are equal to or greater than 25 ⁇ m.
  • the first step in the development of a formulation for the anti-IgE antibody was to determine a suitable buffer and pH for lyophilization and storage ofthe product.
  • Antibody at a concentration of 5.0 mg/mL was formulated into 10 M succinate buffers ranging from pH 5.0 to pH 6.5 and into sodium phosphate, potassium phosphate and histidine buffers at pH 7.0.
  • Figure 9 shows increased antibody aggregate was observed in the higher pH formulations both before and after lyophilization.
  • An exception was the histidine formulation at pH 7, where no increase in aggregate was observed upon storage at 2-8° C.
  • Figure 10 shows rhuMAb E25 lyophilized in 5 mM histidine buffer at both pH 6 and pH 7 and stored for 1 year at 2-8° C. 25° C, and 40° C.
  • the pH 6 formulation had less aggregate than the antibody formulated at pH 7.
  • the anti-IgE antibody was formulated into sodium succinate at pH 5 with or without a lyoprotectant.
  • non-reducing monosaccharide i.e. mannitol
  • reducing disaccharides i.e. lactose and maltose
  • non-reducing disaccharides i.e. trehalose and sucrose.
  • Hydrophobic interaction chromatography ofthe antibody formulated in histidine buffer at pH 6 with lactose shows the antibody is altered following storage for 6 months at 40° C ( Figure 13).
  • the chromatography peaks are broadened and the retention time decreases. These changes are not observed with the buffer control and sucrose formulations stored under similar conditions as shown in Figures 14 and 15, respectively.
  • isoelectric focusing showed an acidic shift in the pi ofthe antibody formulated in lactose and stored at 25° C and 40° C. This indicates that reducing sugars are not suitable as lyoprotectants for the antibody.
  • Isotonic formulation Anti-IgE at 25 mg/mL formulated in 5 mM histidine buffer at pH 6 with 500 moles of sugar per mole antibody which equals a sugar concentration of 85 mM. This formulation is reconstituted with BWFI (0.9% benzyl alcohol) at a volume which is four times less than was filled. This results in a 100 mg/mL of antibody in 20 mM histidine at pH 6 with an isotonic sugar concentration of 340 mM.
  • Hypertonic formulation Anti-IgE at 25 mg/mL formulated in 5 M histidine buffer at pH 6 with 1000 moles of sugar per mole antibody which equals a sugar concentration of 161 mM. This formulation is reconstituted with BWFI (0.9% benzyl alcohol) at a volume which is four times less than was filled. This results in a 100 mg/mL of antibody in 20 mM histidine at pH 6 with a hypertonic sugar concentration of 644 mM.
  • BWFI 0.9% benzyl alcohol
  • IgE receptor inhibition assay It was discovered that the binding activity ofthe isotonic and hypertonic sucrose and trehalose formulations was essentially unchanged following storage at -70° C, 2-8° C, 30° C and 50° C for up to 36 weeks.
  • Lyophilized formulations of proteins are known to contain insoluble aggregates or particulates (Cleland et al. Critical Reviews in Therapeutic Drug Carrier Systems, 10 (4):307-377 (1993)). Accordingly, a particulate assay of antibody lyophilized at a concentration of 25 mg/mL in 5 mM histidine, pH 6 with the addition of 85 mM and 161 mM sucrose and trehalose was performed. Polysorbate 20 was added to the formulations at a concentration of 0.005%, 0.01%, and 0.02%. Samples were lyophilized and assayed following reconstitution to 100 mg/mL antibody in 20 mM histidine, pH 6 with 340 mM and 644 mM sugar. The polysorbate 20 concentration following reconstitution was 0.02%. 0.04%. and 0.08%.
  • Table 9 shows the number of particles of size equal to or greater than 10 ⁇ m and equal to or greater than 25 ⁇ m from the isotonic and hypertonic sucrose and trehalose formulations.
  • Polysorbate 20 was added to the formulations at concentrations of 0.005%. 0.01%, and 0.02% prior to lyophilization. The results show that the addition of TweenTM to the formulation significantly reduces the number of particles in each size range tested.
  • the US Pharmacopeia (USP) specification for small volume injections are not more than 6,000 particles of greater than or equal to 10 ⁇ m and not more than 600 particles of greater than or equal to 25 ⁇ m per container (Cleland et al, supra). With the addition of polysorbate 20, both the hypertonic and isotonic formulations pass this specification.
  • a 10 cc vial is filled with 5.7 L of rhuMAb E25 at a concentration of 25 mg/mL formulated in 5 mM histidine at pH 6.0 with 0.01% polysorbate 20.
  • Sucrose is added as a lyoprotectant at a concentration of 85 mM which co ⁇ esponds to a molar ratio of sugar to antibody of 500 to 1.
  • the vial is lyophilized and reconstituted with 0.9% benzyl alcohol to one quarter ofthe volume ofthe fill or 1.2 mL.
  • the final concentration of components in the formulation is increased four fold to 100 mg/mL rhuMAb E25 in 20 mM histidine at pH 6 with 0.04% polysorbate 20 and 340 mM sucrose (isotonic) and 0.9% benzyl alcohol.
  • the formulation contains histidine buffer at pH 6 because of its demonstrated protective effect on antibody aggregation.
  • Sucrose was added as the lyoprotectant because of previous use in the pharmaceutical industry.
  • the concentration of sugar was chosen to result in an isotonic formulation upon reconstitution.
  • polysorbate 20 is added to prevent the formation of insoluble aggregates.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Formulation de protéine lyophilisée stable pouvant être reconstituée au moyen d'un diluant approprié pour donner une formulation reconstituée à forte concentration en protéine se prêtant à une administration sous-cutanée. Par exemple, des formulations d'anticorps anti-IgE et anti-HER2 ont été préparées par lyophilisation de ces anticorps en présence d'un lyoprotecteur. Le mélange lyophilisé ainsi obtenu est reconstitué pour donner une forte concentration en protéine sans perte apparente de stabilité de la protéine.
EP96925497A 1995-07-27 1996-07-23 Formulation de proteine lyophilisee isotonique et stable Withdrawn EP0845997A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP04022777.9A EP1516628B1 (fr) 1995-07-27 1996-07-23 Formulation de protéine stabile, lyophilisée et isotonique
DK04022777.9T DK1516628T3 (da) 1995-07-27 1996-07-23 Stabil, isotonisk lyofiliseret proteinformulering
EP10178416.3A EP2275119B1 (fr) 1995-07-27 1996-07-23 Formulation de protéine stabile, lyophilisée et isotonique

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US50801495A 1995-07-27 1995-07-27
US508014 1995-07-27
US08/615,369 US6267958B1 (en) 1995-07-27 1996-03-14 Protein formulation
US615369 1996-03-14
PCT/US1996/012251 WO1997004801A1 (fr) 1995-07-27 1996-07-23 Formulation de proteine lyophilisee isotonique et stable

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP04022777.9A Division EP1516628B1 (fr) 1995-07-27 1996-07-23 Formulation de protéine stabile, lyophilisée et isotonique

Publications (1)

Publication Number Publication Date
EP0845997A1 true EP0845997A1 (fr) 1998-06-10

Family

ID=27056058

Family Applications (3)

Application Number Title Priority Date Filing Date
EP10178416.3A Expired - Lifetime EP2275119B1 (fr) 1995-07-27 1996-07-23 Formulation de protéine stabile, lyophilisée et isotonique
EP96925497A Withdrawn EP0845997A1 (fr) 1995-07-27 1996-07-23 Formulation de proteine lyophilisee isotonique et stable
EP04022777.9A Expired - Lifetime EP1516628B1 (fr) 1995-07-27 1996-07-23 Formulation de protéine stabile, lyophilisée et isotonique

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP10178416.3A Expired - Lifetime EP2275119B1 (fr) 1995-07-27 1996-07-23 Formulation de protéine stabile, lyophilisée et isotonique

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP04022777.9A Expired - Lifetime EP1516628B1 (fr) 1995-07-27 1996-07-23 Formulation de protéine stabile, lyophilisée et isotonique

Country Status (18)

Country Link
EP (3) EP2275119B1 (fr)
JP (7) JPH11510170A (fr)
CN (3) CN102416176A (fr)
AR (2) AR003969A1 (fr)
AU (1) AU716785B2 (fr)
BR (1) BR9609743A (fr)
CA (2) CA2745743A1 (fr)
DK (2) DK2275119T3 (fr)
ES (2) ES2435462T3 (fr)
HK (2) HK1117075A1 (fr)
IL (1) IL122910A (fr)
MX (1) MX9800684A (fr)
NO (2) NO323557B1 (fr)
NZ (2) NZ313503A (fr)
PT (2) PT2275119E (fr)
RU (2) RU2497500C2 (fr)
SI (2) SI1516628T1 (fr)
WO (1) WO1997004801A1 (fr)

Families Citing this family (336)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ES2435462T3 (es) * 1995-07-27 2013-12-19 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0852951A1 (fr) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU740284B2 (en) * 1997-06-13 2001-11-01 Genentech Inc. Stabilized antibody formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
CZ302005B6 (cs) * 1998-03-26 2010-09-01 Schering Corporation Vodný prostredek PEG-interferon alfa konjugátu, jeho lyofilizát a výrobek jej obsahující
EP2311436A1 (fr) 1998-04-27 2011-04-20 Altus Pharmaceuticals Inc. Cristaux de protéines stabilisées, formulations renfermant lesdits cristaux et leurs procèdes de fabrication
AU760048B2 (en) * 1998-05-06 2003-05-08 Genentech Inc. Protein purification by ion exchange chromatography
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
CN1053590C (zh) * 1998-10-19 2000-06-21 卫生部长春生物制品研究所 冻干甲型肝炎减毒活疫苗及其保护剂
ES2388341T3 (es) 1998-10-23 2012-10-11 Kirin-Amgen Inc. Péptidos miméticos de trombopoyetina diméricos que se unen al receptor MPL y que tienen actividad trombopoyética
ATE296839T1 (de) 1999-03-01 2005-06-15 Genentech Inc Antikörper zur krebsbehandlung und -diagnose
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
JP4557098B2 (ja) * 1999-03-31 2010-10-06 味の素株式会社 安定な6−アミジノ−2−ナフチル4−グアニジノベンゾエート酸付加塩製剤ならびにその製造方法
CN100448482C (zh) * 1999-05-31 2009-01-07 三菱化学株式会社 Hgf冻干制剂
AU5812800A (en) 1999-06-12 2001-01-02 Stefan Barth Pharmaceutical preparation
DK2283866T3 (en) 1999-06-25 2015-05-18 Genentech Inc METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES
CN101121021B (zh) 1999-06-25 2011-12-07 杰南技术公司 人源化抗ErbB2抗体及用抗ErbB2抗体进行的治疗
EP1064934A1 (fr) 1999-06-30 2001-01-03 Applied Research Systems ARS Holding N.V. Compositions lyophilisées contenant du GRF
CA2382100A1 (fr) 1999-08-27 2001-03-08 Genentech, Inc. Dosages pour traitement avec des anticorps anti-erbb2
EP1229934B1 (fr) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions et methodes de traitement du cancer utilisant des immunoconjugues et des agents chimiotherapeutiques
BR0014486A (pt) * 1999-10-04 2002-09-17 Chiron Corp Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado
EP2292263A3 (fr) * 1999-12-02 2011-07-27 Novartis Vaccines and Diagnostics, Inc. Compositions et procédés pour la stabilisation de molécules biologiques lors de la lyophilisation
ATE293159T1 (de) 1999-12-14 2005-04-15 Thermo Biostar Inc Stabilisierendes verdünnungsmittel für polypeptide und antigene
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
KR101135233B1 (ko) 2000-05-19 2012-04-12 제넨테크, 인크. ErbB 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석
JP2004512262A (ja) 2000-06-20 2004-04-22 アイデック ファーマスーティカルズ コーポレイション 非放射性抗cd20抗体/放射標識抗cd22抗体の組合せ
US8632778B2 (en) 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
CA2422076A1 (fr) 2000-09-18 2002-03-21 Idec Pharmaceutical Corporation Polytherapie pour le traitement de maladies auto-immunes utilisant une combinaison d'anticorps d'immunoregulation/de depletion de cellules b
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
PT1324776E (pt) * 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
CN1501928A (zh) 2000-11-02 2004-06-02 斯隆-凯特林癌症研究所 结合hsp90的小分子组合物
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
EP1370292A1 (fr) 2001-01-31 2003-12-17 Idec Pharmaceuticals Corporation Utilisation d'antagonistes cd23 dans le traitement des troubles neoplasiques
AU2002243718B2 (en) 2001-01-31 2007-12-06 Biogen Idec Inc. Use of immunoregulatory antibodies in the treatment of neoplastic disorders
JP2004529188A (ja) 2001-05-23 2004-09-24 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 上昇に関連した癌の治療法
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CA2385745C (fr) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methodes pour administrer des anticorps anti-tnf.alpha.
DE10133394A1 (de) * 2001-07-13 2003-01-30 Merck Patent Gmbh Flüssige Formulierung enthaltend Cetuximab
JP4317010B2 (ja) 2001-07-25 2009-08-19 ピーディーエル バイオファーマ,インコーポレイティド IgG抗体の安定な凍結乾燥医薬製剤
CN1292655C (zh) * 2001-11-08 2007-01-03 蛋白质设计实验室股份有限公司 IgG抗体稳定的液态药物制剂
CN100415769C (zh) * 2002-02-07 2008-09-03 中国科学院过程工程研究所 寡聚或多聚亚基蛋白质分离纯化的方法
DK1475101T3 (da) 2002-02-14 2011-01-10 Chugai Pharmaceutical Co Ltd Antistof-holdige farmaceutiske opløsninger
DE10211227A1 (de) * 2002-03-13 2003-10-02 Aventis Behring Gmbh Verfahren zur Rekonstitution von Iyophilisierten Proteinen
EP2289942B1 (fr) 2002-04-10 2013-07-31 Genentech, Inc. Variantes d'anticorps anti-HER2
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
AU2003247686A1 (en) * 2002-07-02 2004-01-23 Smithkline Beecham Corporation A novel stable formulation
PL214010B1 (pl) 2002-07-15 2013-06-28 Genentech Inc Rekombinowane humanizowane przeciwcialo 2C4 i zastosowanie tego przeciwciala
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
ES2629602T5 (es) 2002-09-11 2021-06-08 Genentech Inc Purificación de proteínas
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
KR20050110628A (ko) * 2003-02-10 2005-11-23 엘란 파마슈티칼스, 인크. 면역글로불린 제제 및 이의 제조방법
US20050142139A1 (en) * 2003-03-21 2005-06-30 Norbert Schulke CD4-IgG2 formulations
KR101105486B1 (ko) 2003-04-02 2012-01-13 아레스 트레이딩 에스.에이. Fsh 및 lh과 비이온성 계면활성제의 액상 약제학적 제제
ZA200507757B (en) 2003-04-04 2007-01-31 Genentech Inc High concentration antibody and protein formulations
AU2012200957B2 (en) * 2003-04-04 2014-10-23 Genentech, Inc. High concentration antibody and protein formulations
CA2519870A1 (fr) 2003-04-09 2004-10-28 Genentech, Inc. Administration par voie intraveineuse de compositions de rituximab pour traiter l'arthrite rhumatoide
FR2853551B1 (fr) 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
KR20060080535A (ko) 2003-05-14 2006-07-10 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
ZA200509059B (en) 2003-05-30 2007-01-31 Genentech Inc Treatment with anti-VEGF antibodies
CA2526402A1 (fr) 2003-06-05 2005-01-20 Genentech, Inc. Antagonistes de blys et leurs utilisations
CA2526099C (fr) 2003-06-20 2013-02-05 Ares Trading Sa Formulations lyophilisees a base de fsh/lh
BRPI0413276B8 (pt) 2003-08-05 2021-05-25 Novo Nordisk As derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica
US7459021B2 (en) 2003-09-03 2008-12-02 Shmuel Bukshpan Methods and apparatus for rapid crystallization of biomolecules
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
DK2348051T3 (en) 2003-11-05 2019-03-18 Roche Glycart Ag CD20 antibodies with increased fc receptor binding affinity and effector function
DE10355251A1 (de) * 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
WO2005072772A1 (fr) * 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Compositions pharmaceutiques
WO2005089503A2 (fr) * 2004-03-19 2005-09-29 Progenics Pharmaceuticals, Inc. Formulations de cd4-igg2
US7319032B2 (en) 2004-04-22 2008-01-15 Medtox Non-sugar sweeteners for use in test devices
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
DE102004022927A1 (de) * 2004-05-10 2005-12-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg 1,4 O-verknüpfte Saccharose-Derivate zur Stabilisierung von Antikörpern oder Antikörper-Derivaten
US7723306B2 (en) 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
WO2006014965A2 (fr) * 2004-07-27 2006-02-09 Human Genome Sciences, Inc. Preparation pharmaceutique et processus
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006060533A2 (fr) 2004-12-01 2006-06-08 Genentech, Inc. Conjugues medicament anticorps et procedes correspondants
DK1827483T3 (da) 2004-12-15 2014-10-06 Swedish Orphan Biovitrum Ab Publ Terapeutiske formuleringer af keratinocyt-vækstfaktor
CN101141981A (zh) 2005-01-21 2008-03-12 健泰科生物技术公司 Her抗体的固定剂量给药
CN1313161C (zh) * 2005-01-27 2007-05-02 北京大学临床肿瘤学院 结直肠癌放射免疫导向手术药物及其制备方法
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
EP2402374A1 (fr) 2005-02-07 2012-01-04 GlycArt Biotechnology AG Molécules de liaison d'antigène pour lier l'EGFR, vecteurs les codant et utilisations associées
ES2440481T3 (es) 2005-02-23 2014-01-29 Genentech, Inc. Prolongación del tiempo hasta la progresión de la enfermedad o supervivencia en pacientes de cáncer de ovario usando pertuzumab
NZ560713A (en) * 2005-03-25 2010-11-26 Regeneron Pharma VEGF antagonist formulations
NZ564843A (en) * 2005-08-03 2012-05-25 Immunogen Inc Immunoconjugate formulations comprising an immunoconjugate and an excipient in a buffered aqueous solution
TWI478940B (zh) 2005-08-26 2015-04-01 Roche Glycart Ag 具有經改變細胞傳訊活性之改質抗原結合分子
CN101312744A (zh) * 2005-11-22 2008-11-26 惠氏公司 免疫球蛋白融合蛋白制剂
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
PE20071063A1 (es) * 2005-12-20 2007-10-24 Bristol Myers Squibb Co Formulaciones de proteinas estables
US10508144B2 (en) 2005-12-20 2019-12-17 Bristol-Myers Squibb Company Carbohydrate content of CTLA4 molecules
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
PL1969004T3 (pl) 2005-12-28 2012-01-31 Novo Nordisk As Kompozycje zawierające acylowaną insulinę i cynk oraz sposób wytwarzania tych kompozycji
EP2361613B1 (fr) * 2006-02-07 2020-08-12 Shire Human Genetic Therapies, Inc. Compositions stabilisées de protéines possédant une fraction de thiol libre
NZ571068A (en) 2006-03-21 2012-06-29 Genentech Inc An antibody that can bind human alpha5beta1
EP2389950A1 (fr) 2006-03-23 2011-11-30 Novartis AG Thérapeutique anticorps antigène de cellules anti-tumorales
TW201333030A (zh) 2006-04-05 2013-08-16 Abbott Biotech Ltd 抗體之純化
WO2007120656A2 (fr) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Utilisations et compositions pour le traitement de la polyarthrite rhumatoïde
AU2011265555B2 (en) * 2006-04-21 2016-03-10 Amgen Inc. Lyophilized therapeutic peptibody formulations
US9283260B2 (en) * 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
KR101406811B1 (ko) 2006-06-16 2014-06-12 리제너론 파마슈티칼스 인코포레이티드 유리체내 투여에 적당한 vegf 길항제 제형
AR062223A1 (es) 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
CN101199483B (zh) * 2006-12-14 2011-01-26 上海中信国健药业股份有限公司 一种稳定的抗her2人源化抗体制剂
CN101199845B (zh) * 2006-12-14 2012-05-23 上海国健生物技术研究院 一种稳定的抗IgE人源化单抗制剂
AU2008204901A1 (en) * 2007-01-09 2008-07-17 Wyeth Anti-IL-13 antibody formulations and uses thereof
RU2475265C2 (ru) 2007-01-16 2013-02-20 Эбботт Лэборетриз Способы лечения псориаза
MX2009008692A (es) * 2007-02-16 2009-08-21 Wyeth Corp Uso de sacarosa para suprimir la agregacion de proteina inducida por manitol.
CL2008000614A1 (es) 2007-03-02 2008-09-05 Genentech Inc F Hoffmann La Ro Metodo para tratar un paciente con un tipo de cancer que expresa el receptor her3 a un nivel bajo mediante la administracion de un inhibidor de la dimerizacion de her.
AU2008233173B2 (en) 2007-03-29 2013-09-19 Abbvie Inc. Crystalline anti-human IL-12 antibodies
EP2171451A4 (fr) 2007-06-11 2011-12-07 Abbott Biotech Ltd Procédés de traitement de l'arthrite idiopathique juvénile
WO2008152106A1 (fr) 2007-06-13 2008-12-18 Novo Nordisk A/S Formulation pharmaceutique contenant un dérivé d'insuline
US8709731B2 (en) 2007-08-24 2014-04-29 Oncotherapy Science, Inc. DKK1 oncogene as therapeutic target for cancer and a diagnosing marker
RU2010111120A (ru) 2007-08-24 2011-09-27 Онкотерапи Сайенс, Инк. (Jp) Eb13, dlx5, nptx1 и cdkn3 в качестве генов-мишеней для терапии и диагностики рака легкого
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
KR20090056543A (ko) * 2007-11-30 2009-06-03 주식회사 녹십자 B형 간염 바이러스(hbv) 중화 인간 항체를 포함하는약학적 제제
JP5784907B2 (ja) 2007-12-28 2015-09-24 バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated 組換え型vwf製剤
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
EP2237797A4 (fr) 2008-01-03 2012-11-07 Scripps Research Inst Ciblage d'anticorps par domaine de reconnaissance modulaire
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
ATE548052T1 (de) 2008-01-17 2012-03-15 Philogen Spa Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler
AR070141A1 (es) 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至her2結構域ii之抗體及其酸性變異體的組合物
BRPI0822447A2 (pt) 2008-03-14 2015-06-16 Biocon Ltd Anticorpo monoclonal e método do mesmo
CY1112212T1 (el) * 2008-04-24 2015-12-09 Immatics Biotechnologies Gmbh Νεα σκευασματα πεπτιδιων που σχετιζονται με ογκους τα οποια συνδεονται σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης i ή ii για εμβολια
PL2113253T3 (pl) * 2008-04-30 2010-09-30 Immatics Biotechnologies Gmbh Nowa postać leku - preparat zawierający peptydy nowotworowe wiążące się z antygenami ludzkich leukocytów klasy I i II, zastosowany w szczepionce
US8093018B2 (en) 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
CN102159248B (zh) 2008-07-15 2013-09-11 健泰科生物技术公司 蒽环类衍生物缀合物、它们的制备方法以及它们作为抗肿瘤化合物的用途
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
CN103919736A (zh) 2008-10-21 2014-07-16 巴克斯特国际公司 冻干的重组vwf配方
US9393304B2 (en) * 2008-10-29 2016-07-19 Ablynx N.V. Formulations of single domain antigen binding molecules
CN102272154A (zh) 2008-10-29 2011-12-07 惠氏有限责任公司 单域抗原结合性分子的纯化方法
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
CA2744158A1 (fr) 2008-11-22 2010-05-27 Genentech, Inc. Therapie antiangiogenese pour le traitement du cancer du sein
EP2196476A1 (fr) 2008-12-10 2010-06-16 Novartis Ag Formulation d'anticorps
FR2940617B1 (fr) * 2008-12-30 2012-04-20 Fractionnement Et Des Biotechonologies Lab Franc Composition d'immunoglobulines g
AU2010221156A1 (en) 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
TWI504409B (zh) 2009-03-25 2015-10-21 Genentech Inc 新穎抗-α5β1抗體及其用途
EP2413965A1 (fr) 2009-03-31 2012-02-08 Roche Glycart AG Traitement du cancer par un anticorps anti-igg1 egfr humanisé et par de l'irinotécane
AR075998A1 (es) 2009-04-01 2011-05-11 Genentech Inc Tratamiento de trastornos resistentes a insulina.composicion farmaceutica. uso. kit
WO2010146059A2 (fr) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarqueurs pour une thérapie par inhibiteur d'igf-1r
RU2733466C2 (ru) 2009-07-28 2020-10-01 Шайр Хьюман Дженетик Терапиз Композиции и способы для лечения болезни гоше
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
BR112012003346A2 (pt) 2009-08-15 2016-11-16 Genentech Inc metodo de tratamento de um paciente diagnostico com cancer de mama metastico previamente tratado kit para tratamento de cancer de mama metastatico previamente tratado em um paciente humano metodo para instruir um paciente humano com cancer metodo promocional e metodo comercial
AU2010292172A1 (en) 2009-09-09 2012-05-03 Centrose, Llc Extracellular targeted drug conjugates
AR078161A1 (es) * 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
ES2787403T3 (es) 2009-10-01 2020-10-16 Hoffmann La Roche Filtración final de múltiples etapas
MX2012005863A (es) * 2009-11-20 2013-01-18 Centro Inmunologia Molecular Formulaciones de anticuerpos.
CA2781682A1 (fr) 2009-12-04 2011-06-09 Genentech, Inc. Anticorps plurispecifiques, analogues d'anticorps, compositions et procedes
DK2512450T3 (en) 2009-12-15 2018-04-23 Ascendis Pharma Endocrinology Div A/S Dry growth hormone composition transiently bound to a polymer carrier
US20110158987A1 (en) * 2009-12-29 2011-06-30 F. Hoffmann-Laroche Ag Novel antibody formulation
TWI505838B (zh) 2010-01-20 2015-11-01 Chugai Pharmaceutical Co Ltd Stabilized antibody solution containing
US20110200595A1 (en) 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
BR112012020303A2 (pt) 2010-02-19 2019-09-24 Cadila Pharmaceuticals Ltd "composição estável de células mortas com propriedades imunogênicas substancialmente retidas, e, processo e método de preparação da composição."
JP2013520442A (ja) 2010-02-23 2013-06-06 ジェネンテック, インコーポレイテッド 卵巣癌の治療のための抗血管新生治療
NZ602685A (en) 2010-03-01 2014-10-31 Cytodyn Inc Concentrated protein formulations and uses thereof
USRE47150E1 (en) 2010-03-01 2018-12-04 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
EP2898890B1 (fr) 2010-03-31 2019-08-21 Stabilitech Biopharma Ltd Stabilisation de particules virales
KR101884953B1 (ko) 2010-03-31 2018-08-02 스타빌리테크 리미티드 바이러스 입자, 폴리펩타이드 또는 생물학적 물질의 안정화를 위한 부형제
ES2708989T3 (es) 2010-03-31 2019-04-12 Stabilitech Biopharma Ltd Método de conservación de adyuvantes de alumbre y vacunas potenciadas con alumbre
WO2011134979A2 (fr) * 2010-04-27 2011-11-03 Scil Technology Gmbh Préparation stable de mia/cd-rap
WO2011146568A1 (fr) 2010-05-19 2011-11-24 Genentech, Inc. Prédiction de réponses à un inhibiteur de her
WO2011153243A2 (fr) 2010-06-02 2011-12-08 Genentech, Inc. Thérapie anti-angiogénique utilisée dans le traitement du cancer de l'estomac
CN103068367B (zh) 2010-06-24 2016-09-07 弗·哈夫曼-拉罗切有限公司 用于稳定含有蛋白质的制剂的含有烷基糖苷的组合物和方法
WO2012003470A2 (fr) * 2010-07-02 2012-01-05 Medimmune, Llc Formulations d'anticorps
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
EP2596128B1 (fr) 2010-07-22 2015-04-22 President and Fellows of Harvard College Circuits classificateurs biologiques à entrées multiples pour cellules
WO2012012750A1 (fr) 2010-07-23 2012-01-26 Trustees Of Boston University Inhibiteurs anti-despr comme agents thérapeutiques pour l'inhibition de l'angiogenèse pathologique et de l'invasivité des cellules tumorales et pour l'imagerie moléculaire et l'administration ciblée
JP5918246B2 (ja) * 2010-10-06 2016-05-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. 抗インターロイキン−4受容体(il−4r)抗体を含有する安定化製剤
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
JP6034797B2 (ja) 2010-12-02 2016-11-30 オンコリティクス バイオテク,インコーポレーテッド 凍結乾燥されたウイルス製剤
KR101875245B1 (ko) 2010-12-02 2018-08-02 온콜리틱스 바이오테크 인코포레이티드 액체 바이러스 제형
CA2820095C (fr) 2010-12-21 2019-02-26 F. Hoffmann-La Roche Ag Preparation d'anticorps enrichie en isoformes et son procede d'obtention
CN102028661B (zh) * 2010-12-31 2012-05-23 山东新时代药业有限公司 聚乙二醇化重组人粒细胞集落刺激因子冻干粉针剂及其制备方法
WO2012097019A1 (fr) 2011-01-13 2012-07-19 Regeneron Pharmaceuticals, Inc. Utilisation d'antagoniste de vegf pour traiter des troubles oculaires angiogéniques
SI2691112T1 (en) 2011-03-31 2018-07-31 Merck Sharp & Dohme Corp. STABILITY FORMULATION PROTITELES FOR HUMAN PROGRAMMED DEPRESSOR RECEPTOR PD-1 AND RELATED HEALTH
WO2012149197A2 (fr) 2011-04-27 2012-11-01 Abbott Laboratories Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante
AU2012258637B2 (en) 2011-05-24 2017-07-20 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Fgf-18之凍乾調配物
WO2013012022A1 (fr) 2011-07-19 2013-01-24 中外製薬株式会社 Préparation à teneur en protéines stable renfermant de l'argininamide ou un composé analogue correspondant
US20130022551A1 (en) 2011-07-22 2013-01-24 Trustees Of Boston University DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
IL301603A (en) 2011-10-14 2023-05-01 Genentech Inc Pertuzumab, trastuzumab, docetaxel and carboplatin for use in the preoperative treatment of a patient
PE20141413A1 (es) * 2011-10-25 2014-10-25 Onclave Therapeutics Ltd Formulaciones de anticuerpo y metodos
WO2013091903A1 (fr) 2011-12-22 2013-06-27 Novo Nordisk A/S Anticorps anti-canal crac
US20130195851A1 (en) 2011-12-23 2013-08-01 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
CN102512384B (zh) * 2011-12-29 2014-11-26 嘉和生物药业有限公司 一种冻干剂型蛋白组合物及其制备方法
DK2825558T3 (da) 2012-03-13 2019-07-22 Hoffmann La Roche Kombinationsterapi til behandling af ovariecancer
AU2013240261A1 (en) 2012-03-27 2014-09-18 Genentech, Inc. Diagnosis and treatments relating to HER3 inhibitors
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
KR102326359B1 (ko) * 2012-05-18 2021-11-12 제넨테크, 인크. 고농도 모노클로날 항체 제제
WO2013176754A1 (fr) 2012-05-24 2013-11-28 Abbvie Inc. Nouvelle purification d'anticorps au moyen de chromatographie à interaction hydrophobe
US20140017318A1 (en) * 2012-07-10 2014-01-16 Kevin O'Connell Method to produce a medicinal product comprising a biologically active protein and the resulting product
CA2880767A1 (fr) 2012-08-07 2014-02-13 Genentech, Inc. Polytherapie pour le traitement d'un glioblastome
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
BR112015004467A2 (pt) 2012-09-02 2017-03-21 Abbvie Inc método para controlar a heterogeneidade de proteínas
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014045081A1 (fr) 2012-09-18 2014-03-27 Adocia Composition pharmaceutique stable, comprenant une solution aqueuse d'une protéine thérapeutiquement active dérivée d'un anticorps
US20150216977A1 (en) 2012-09-18 2015-08-06 Adocia Stable pharmaceutical composition, comprising an aqueous solution of an antibody-derived therapeutically active protein
EP2911692B1 (fr) 2012-10-26 2019-08-21 The University of Queensland Utilisation d'inhibiteurs de l'endocytose et d'anticorps pour une thérapie anticancéreuse
WO2014068029A1 (fr) * 2012-10-31 2014-05-08 Takeda Gmbh Formulation lyophilisée comprenant un composé neutralisant gm-csf
ES2773103T3 (es) * 2012-12-21 2020-07-09 Ichnos Sciences SA Formulación de anticuerpos anti HER2
CA2905010A1 (fr) 2013-03-12 2014-09-18 Abbvie Inc. Anticorps humains qui se lient au tnf-alpha et leurs procedes de preparation
WO2014151878A2 (fr) 2013-03-14 2014-09-25 Abbvie Inc. Procédés pour la modulation des profils de glycosylation de protéines de traitements à base de protéines recombinantes au moyen de monosaccharides et d'oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014159579A1 (fr) 2013-03-14 2014-10-02 Abbvie Inc. Anticorps anti-tnfα ayant mutés et leurs procédés d'utilisation
CN105451767B (zh) 2013-03-15 2019-10-18 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
WO2014140361A1 (fr) * 2013-03-15 2014-09-18 Takeda Gmbh Formulation d'un anticorps et son utilisation
WO2014177623A1 (fr) 2013-04-30 2014-11-06 Novo Nordisk A/S Schéma d'administration d'un nouveau type
NZ746944A (en) 2013-07-23 2021-07-30 Biocon Ltd Use of a cd6 binding partner and method based thereon
EP3889178A1 (fr) 2013-08-30 2021-10-06 Takeda GmbH Anticorps neutralisant le gm-csf destiné à être utilisé dans le traitement de la polyarthrite rhumatoïde ou comme analgésique
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US10617764B2 (en) 2013-11-21 2020-04-14 Genmab A/S Lyophilized anti-tissue factor antibody-drug conjugates
CN104707146B (zh) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
JP2017506640A (ja) 2014-02-14 2017-03-09 セントローズ, エルエルシー 細胞外標的化薬物共役体
CN103893135B (zh) * 2014-03-28 2017-01-11 中国医学科学院输血研究所 一种人血浆蛋白c的冻干稳定剂组合物及其用途
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
EP3131584B1 (fr) 2014-04-16 2022-01-12 Biocon Limited Formulations de protéines stables comprenant un excès molaire de sorbitol
CN106659785B (zh) * 2014-05-07 2021-04-30 武田有限公司 包含gm-csf中和化合物的液体制剂
CN114057895A (zh) * 2014-05-28 2022-02-18 诺诺公司 TAT-NR2B9c的氯盐
EP3613433B1 (fr) 2014-05-30 2022-01-05 Shanghai Henlius Biotech, Inc. Anticorps du récepteur du facteur de croissance anti-épidermique (egfr)
JP6655074B2 (ja) 2014-06-20 2020-02-26 ジェネンテック, インコーポレイテッド シャガシンに基づく足場組成物、方法及び使用
JP6634394B2 (ja) * 2014-06-26 2020-01-22 アムジェン インコーポレイテッド タンパク質製剤
WO2016019969A1 (fr) 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Anticorps bispécifiques administrés par voie sous-cutanée, destinés à être utilisés dans le traitement du cancer
EP3567056A1 (fr) 2014-09-10 2019-11-13 F. Hoffmann-La Roche AG Anticorps d'immunoglobuline 1 traités au galactose
BR112017010498A2 (pt) 2014-11-19 2017-12-26 Axon Neuroscience Se anticorpos tau humanizados em doença de alzheimer
JP2018506275A (ja) 2015-01-28 2018-03-08 ジェネンテック, インコーポレイテッド 多発性硬化症の遺伝子発現マーカー及び治療
CN107106671B (zh) 2015-04-03 2022-01-14 优瑞科生物技术公司 靶向afp肽/mhc复合体的构建体及其用途
US11077193B2 (en) 2015-04-21 2021-08-03 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Nerve growth factor composition and powder injection
CN108348579B (zh) 2015-04-21 2021-04-27 舒泰神(北京)生物制药股份有限公司 神经生长因子组合物及注射粉剂
AU2016252773B2 (en) 2015-04-24 2022-06-02 Genentech, Inc. Multispecific antigen-binding proteins
BR112017024610A2 (pt) 2015-06-24 2018-07-31 F. Hoffmann-La Roche Ag anticorpos para receptor antitransferrina com afinidade especificada
JP2018523684A (ja) 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗pcsk9阻害抗体
CN114031689A (zh) 2015-10-02 2022-02-11 豪夫迈·罗氏有限公司 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
JP2018529747A (ja) 2015-10-06 2018-10-11 ジェネンテック, インコーポレイテッド 多発性硬化症を治療するための方法
ES2956007T3 (es) 2015-12-03 2023-12-11 Regeneron Pharma Métodos de asociación de variantes genéticas con un resultado clínico en pacientes que padecen degeneración macular asociada a la edad tratados con anti-VEGF
CA3010564C (fr) 2016-01-12 2024-01-30 Intron Biotechnology, Inc. Composition antibacterienne et methode de traitement d'infections a staphylocoques a l'aide de la composition antibacterienne
UA125388C2 (uk) * 2016-01-12 2022-03-02 Інтрон Байотекнолоджі, Інк. Спосіб виготовлення ліофілізованої композиції
US20190030180A1 (en) 2016-01-13 2019-01-31 Genmab A/S Formulation for antibody and drug conjugate thereof
CN108699155B (zh) 2016-03-01 2023-03-21 豪夫迈·罗氏有限公司 具有改变的细胞死亡诱导的奥滨尤妥珠单抗变体
WO2017160835A1 (fr) * 2016-03-14 2017-09-21 The Regents Of The University Of Michigan Technique de traitement de lyophilisation médiée par la tension superficielle pour la conservation de produits biologiques
JP7181091B2 (ja) 2016-05-10 2022-11-30 ジェネンテック, インコーポレイテッド ポリペプチドの組み換え産生中にトリスルフィド結合を減少させる方法
LT3463308T (lt) * 2016-06-01 2022-02-10 Servier IP UK Limited Polialkilenoksido-asparaginazės vaisto formos ir jų gamybos būdai bei panaudojimas
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
JP2019534858A (ja) 2016-09-09 2019-12-05 ジェネンテック, インコーポレイテッド Frizzledの選択的ペプチド阻害剤
KR102391338B1 (ko) 2016-09-16 2022-04-26 상하이 헨리우스 바이오테크, 인크. 항-pd-1 항체
AU2017341067B2 (en) * 2016-10-07 2023-10-26 Regeneron Pharmaceuticals, Inc. Room temperature stable lyophilized protein
JP7071974B2 (ja) 2016-10-21 2022-05-19 バイオコン・リミテッド モノクローナル抗体および狼瘡の処置のための使用の方法
CA3044274A1 (fr) 2016-11-21 2018-05-24 Obi Pharma, Inc. Molecules biologiques conjuguees, compositions pharmaceutiques et procedes
EP3556379A4 (fr) 2016-12-15 2020-08-19 Talengen International Limited Méthode et médicament pour la prévention et le traitement de l'obésité
US20190328848A1 (en) 2016-12-15 2019-10-31 Talengen International Limited Method for preventing and treating drug-induced renal injury
EP3556392B1 (fr) 2016-12-15 2024-04-17 Talengen International Limited Plasminogène pour le traitement du diabète
CN110114080A (zh) 2016-12-15 2019-08-09 泰伦基国际有限公司 一种预防和治疗皮肤纤维化的方法
EP3556381A4 (fr) 2016-12-15 2020-09-23 Talengen International Limited Médicament pour la prévention et le traitement de l'ostéoporose et ses utilisations
JP7158740B2 (ja) 2016-12-15 2022-10-24 タレンゲン インターナショナル リミテッド 冠状動脈アテローム性硬化症およびその合併症を治療するための方法
EP3556385A4 (fr) 2016-12-15 2020-12-30 Talengen International Limited Procédé pour atténuer une maladie cardiaque
JP6914336B2 (ja) 2016-12-28 2021-08-04 ジェネンテック, インコーポレイテッド 進行したher2発現がんの治療
EP3568468A4 (fr) 2017-01-12 2020-12-30 Eureka Therapeutics, Inc. Produits de recombinaison ciblant les complexes peptide histone h3/mhc, et leurs utilisations
PT3570884T (pt) 2017-01-17 2020-11-24 Hoffmann La Roche Formulações subcutâneas de anticorpo do her2
US20210330801A1 (en) 2017-03-02 2021-10-28 Cadila Healthcare Limited Novel protein drug conjugate formulation
CN116531511A (zh) 2017-03-02 2023-08-04 豪夫迈·罗氏有限公司 Her2阳性乳腺癌的辅助治疗
EP3615574A4 (fr) 2017-04-26 2021-02-24 Eureka Therapeutics, Inc. Constructions reconnaissant spécifiquement le glypicane 3 et utilisations de ces dernieres
EP3618871A4 (fr) 2017-05-02 2021-01-06 Merck Sharp & Dohme Corp. Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
WO2018210230A1 (fr) * 2017-05-16 2018-11-22 江苏恒瑞医药股份有限公司 Composition pharmaceutique à base d'anticorps anti-pd-l1 et son utilisation
BR112020007736A2 (pt) 2017-10-30 2020-10-20 F. Hoffmann-La Roche Ag composição e método de tratamento
CA3123318A1 (fr) 2017-12-15 2019-06-20 Talengen International Limited Methode et medicament pour prevenir ou traiter l'arthrose
SG11202008098TA (en) 2018-03-28 2020-10-29 Axon Neuroscience Se Antibody-based methods of detecting and treating alzheimer's disease
EP3773721A4 (fr) * 2018-04-13 2022-01-26 Genentech, Inc. Formulations d'immunoconjugué anti-cd79b stables
JOP20200275A1 (ar) 2018-05-10 2020-11-02 Regeneron Pharma صيغ تحتوي على بروتين اندماج لمستقبلvegf مرتفعة التركيز
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN112533952B (zh) 2018-06-01 2023-03-07 大有华夏生物医药集团有限公司 治疗疾病或病况的组合物及其用途
EP3806904A4 (fr) 2018-06-18 2022-04-27 Eureka Therapeutics, Inc. Constructions ciblant un antigène membranaire spécifique à la prostate (psma) et leurs utilisations
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
WO2020061374A1 (fr) 2018-09-20 2020-03-26 Mandalmed, Inc. Méthodes et compositions pour la prévention, le traitement et l'inversion d'une fibrose hépatique
WO2020089743A1 (fr) * 2018-11-02 2020-05-07 Cadila Healthcare Limited Composition pharmaceutique de l-asparaginase pégylée
EA202191058A1 (ru) 2018-11-16 2021-10-07 Мемориал Слоун Кеттеринг Кэнсер Сентр Антитела против муцина-16 и способы их применения
GB201820554D0 (en) 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
GB201820547D0 (en) 2018-12-17 2019-01-30 Oxford Univ Innovation Modified antibodies
CN111375057A (zh) * 2018-12-28 2020-07-07 上海复宏汉霖生物技术股份有限公司 一种包含抗Her2单克隆抗体的药物配制剂
CN112121150A (zh) * 2019-06-24 2020-12-25 杭州生物医药创新研究中心 一种成纤维细胞生长因子10冻干粉
CN112300279A (zh) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
EP3808777A1 (fr) 2019-10-16 2021-04-21 Glenmark Specialty S.A. Formulations d'anticorps liquides stables
US20230066726A1 (en) 2020-01-17 2023-03-02 Talengen International Limited Method for treatment of nerve injury and related disease
JP7487970B2 (ja) 2020-02-06 2024-05-21 タレンゲン インターナショナル リミテッド 多発性硬化症を予防及び治療する方法並びに薬剤
WO2021170071A1 (fr) 2020-02-28 2021-09-02 Shanghai Henlius Biotech, Inc. Constructions anti-cd137, anticorps multispécifique et leurs utilisations
BR112022016491A2 (pt) 2020-02-28 2022-10-11 Shanghai Henlius Biotech Inc Construto anti-cd137 e usos do mesmo
EP4122488A4 (fr) 2020-03-24 2023-04-05 Talengen International Limited Procédé et médicament pour le traitement de la maladie d'alzheimer
EP4122490A4 (fr) 2020-03-24 2023-04-05 Talengen International Limited Procédé et médicament pour le traitement de la maladie de parkinson
WO2021190562A1 (fr) 2020-03-24 2021-09-30 泰伦基国际有限公司 Méthode et médicament pour favoriser la dégradation d'une protéine mal repliée et d'un agrégat de celle-ci
TWI787767B (zh) 2020-03-24 2022-12-21 大陸商深圳瑞健生命科學研究院有限公司 一種治療亨廷頓病的方法和藥物
CN113993900B (zh) 2020-05-27 2023-08-04 舒泰神(北京)生物制药股份有限公司 特异性识别神经生长因子的抗体及其用途
CA3185858A1 (fr) 2020-06-02 2021-12-09 Dynamicure Biotechnology Llc Constructions anti-cd93 et leurs utilisations
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
GB202008860D0 (en) 2020-06-11 2020-07-29 Univ Oxford Innovation Ltd BTLA antibodies
CN115996704A (zh) * 2020-06-12 2023-04-21 伊克诺斯科学公司 抗体制剂稀释剂
CN113827717A (zh) * 2020-06-23 2021-12-24 三生国健药业(上海)股份有限公司 抗her2单克隆抗体冻干制剂及制备方法
BR112023000400A2 (pt) 2020-07-10 2023-03-21 Shanghai Jemincare Pharmaceutical Co Ltd Anticorpo anti-ige engenheirado e aplicação do mesmo
CN116783215A (zh) 2020-07-29 2023-09-19 当康生物技术有限责任公司 抗cd93构建体及其用途
US20220064320A1 (en) 2020-08-14 2022-03-03 Hoffmann-La Roche Inc. Methods for treating multiple sclerosis with ocrelizumab
CN114246944A (zh) * 2020-09-24 2022-03-29 盛禾(中国)生物制药有限公司 一种双特异性抗体的药物组合物及其用途
CN112684177B (zh) * 2020-12-17 2024-05-28 北京维德维康生物技术有限公司 一种乳品多因子快速检测试剂盒及其检测方法
CN117715933A (zh) 2021-03-05 2024-03-15 当康生物技术有限责任公司 抗vista的构建体及其用途
JP2024511424A (ja) 2021-03-25 2024-03-13 ダイナミキュア バイオテクノロジー エルエルシー 抗igfbp7構築物およびその使用
EP4355785A1 (fr) 2021-06-17 2024-04-24 Amberstone Biosciences, Inc. Constructions anti-cd3 et utilisations associées
TW202317633A (zh) 2021-07-08 2023-05-01 美商舒泰神(加州)生物科技有限公司 特異性識別tnfr2的抗體及其用途
WO2023284714A1 (fr) 2021-07-14 2023-01-19 舒泰神(北京)生物制药股份有限公司 Anticorps reconnaissant spécifiquement cd40 et son application
WO2023019556A1 (fr) * 2021-08-20 2023-02-23 齐鲁制药有限公司 Préparation d'anticorps anti-her2 à haute concentration et son utilisation
WO2024020407A1 (fr) 2022-07-19 2024-01-25 Staidson Biopharma Inc. Anticorps reconnaissant spécifiquement l'atténuateur de lymphocytes b et t (btla) et leurs utilisations
WO2024037633A2 (fr) 2022-08-19 2024-02-22 Evive Biotechnology (Shanghai) Ltd Formulations comprenant g-csf et leurs utilisations
WO2024054929A1 (fr) 2022-09-07 2024-03-14 Dynamicure Biotechnology Llc Constructions anti-vista et leurs utilisations
CN115746082A (zh) * 2022-12-02 2023-03-07 大连工业大学 一种调控糖基化鳕鱼蛋白结构的方法及其在制备高内相乳液中的应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5896028A (ja) * 1981-11-30 1983-06-07 Takeda Chem Ind Ltd ヒトIgEの製造法
US4482483A (en) * 1983-04-06 1984-11-13 Armour Pharmceutical Company Composition of intravenous immune globulin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0229810B1 (fr) * 1985-07-09 1991-10-16 Quadrant Bioresources Limited Protection des proteines et similaires
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JPH0827283B2 (ja) * 1986-03-10 1996-03-21 財団法人化学及血清療法研究所 免疫凝集反応用組成物
US4806343A (en) * 1986-03-13 1989-02-21 University Of Southwestern Louisiana Cryogenic protectant for proteins
JPS62289523A (ja) * 1986-06-09 1987-12-16 Green Cross Corp:The 静脈投与用免疫グロブリンの加熱処理方法
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク,インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5262296A (en) * 1988-03-30 1993-11-16 Toray Industries, Inc. Freeze-dried composition containing enzyme-labeled anti-human interferon-β antibody and enzyme immunoassay kit containing the composition
JPH01268645A (ja) * 1988-04-18 1989-10-26 Teijin Ltd シュワルツマン反応抑制剤
EP0417193B1 (fr) * 1988-05-27 1993-08-04 Centocor, Inc. Preparation lyophilisee pour la stabilisation de produits a base d'anticorps
CN1047342A (zh) * 1989-05-13 1990-11-28 杭州市中心血站 因子viii的生产及其病毒灭活方法
WO1991000289A2 (fr) * 1989-06-23 1991-01-10 The Liposome Company, Inc. Liposomes cibles et procedes d'accouplement de liposomes-proteines
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5011676A (en) * 1990-03-27 1991-04-30 Thomas Jefferson University Method to directly radiolabel antibodies for diagnostic imaging and therapy
AU662311B2 (en) * 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
JPH0565233A (ja) * 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
EP0586505A1 (fr) 1991-05-14 1994-03-16 Repligen Corporation Anticorps d'heteroconjugues pour le traitement des infections a l'hiv
WO1992022653A1 (fr) 1991-06-14 1992-12-23 Genentech, Inc. Procede de production d'anticorps humanises
EP0609265B1 (fr) * 1991-10-11 1997-05-28 Abbott Laboratories Composition de reactif en dose unitaire pour dosages par liaison specifique
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
US5290764A (en) * 1992-01-14 1994-03-01 The Dupont Merck Pharmaceutical Company Stabilization of active plasminogen activator inhibitor-1
WO1994004690A1 (fr) 1992-08-17 1994-03-03 Genentech, Inc. Immunoadhesines bispecifiques
FR2700471B1 (fr) * 1993-01-21 1995-04-07 Pasteur Merieux Serums Vacc Utilisation d'anticorps monoclonaux anti-LFA-1 pour la préparation d'un médicament destiné à prévenir le rejet des greffes d'organes solides et médicaments obtenus.
ES2153418T3 (es) * 1993-02-23 2001-03-01 Genentech Inc Estabilizacion de polipeptidos tratados con solventes organicos por medio de excipientes.
FR2708467B1 (fr) * 1993-07-30 1995-10-20 Pasteur Merieux Serums Vacc Préparations d'immunoglobulines stabilisées et procédé pour leur préparation.
DE4344824C1 (de) 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
WO1995033488A1 (fr) 1994-06-02 1995-12-14 Quadrant Holdings Cambridge Limited Procede prevenant l'aggregation de differentes substances lors de rehydratations et de decongelations, et compositions obtenues
ES2435462T3 (es) * 1995-07-27 2013-12-19 Genentech, Inc. Formulación de proteína liofilizada isotónica estable

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9704801A1 *

Also Published As

Publication number Publication date
AU716785B2 (en) 2000-03-09
CN1539505A (zh) 2004-10-27
ES2434840T3 (es) 2013-12-17
AR003969A1 (es) 1998-09-30
CN100360184C (zh) 2008-01-09
CA2226575C (fr) 2011-10-18
EP1516628B1 (fr) 2013-08-21
SI1516628T1 (sl) 2013-10-30
IL122910A0 (en) 1998-08-16
AU6599296A (en) 1997-02-26
JP2017039778A (ja) 2017-02-23
CN1191490A (zh) 1998-08-26
JP2007217430A (ja) 2007-08-30
JP5043506B2 (ja) 2012-10-10
EP1516628A1 (fr) 2005-03-23
NO323557B3 (no) 2007-06-11
HK1117075A1 (en) 2009-01-09
JP2016033156A (ja) 2016-03-10
IL122910A (en) 2002-05-23
NZ313503A (en) 2000-01-28
DK2275119T3 (da) 2013-11-11
WO1997004801A1 (fr) 1997-02-13
PT1516628E (pt) 2013-09-24
AR074517A2 (es) 2011-01-26
EP2275119A1 (fr) 2011-01-19
BR9609743A (pt) 1999-03-02
NZ500539A (en) 2001-11-30
JPH11510170A (ja) 1999-09-07
NO980335D0 (no) 1998-01-26
MX9800684A (es) 1998-04-30
PT2275119E (pt) 2013-11-21
RU2013141049A (ru) 2015-03-20
ES2435462T3 (es) 2013-12-19
EP2275119B1 (fr) 2013-09-25
HK1152876A1 (en) 2012-03-16
CN1151842C (zh) 2004-06-02
JP2011256205A (ja) 2011-12-22
NO980335L (no) 1998-03-26
CA2745743A1 (fr) 1997-02-13
JP2011256206A (ja) 2011-12-22
RU2497500C2 (ru) 2013-11-10
CN102416176A (zh) 2012-04-18
NO323557B1 (no) 2007-06-11
CA2226575A1 (fr) 1997-02-13
JP2007238628A (ja) 2007-09-20
SI2275119T1 (sl) 2013-12-31
NO2007012I1 (no) 2007-11-29
DK1516628T3 (da) 2013-09-08
JP5043507B2 (ja) 2012-10-10

Similar Documents

Publication Publication Date Title
US9283273B2 (en) Protein formulation
CA2226575C (fr) Formulation de proteine lyophilisee isotonique et stable
US6685940B2 (en) Protein formulation
RU2229288C2 (ru) Стабильная изотоническая лиофилизированная протеиновая композиция
MXPA98000684A (en) Formulation of isotonic protocols isotonic s
PT1771208E (pt) Utilização de derivados de tioflavina radiorotulados em imagiologia amiloide para avaliar terapias anti-amiloide
IL155002A (en) Stable liquid compositions containing monoclonal antibody, a method for reducing the kinematic viscosity of such a composition, and a production cow containing a container containing such a composition
JP2014148555A (ja) タンパク質の処方
AU746668B2 (en) Protein formulation
CA2751188A1 (fr) Formulations de proteine concentrees a viscosite reduite

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980216

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 980216;LT PAYMENT 980216;LV PAYMENT 980216;SI PAYMENT 980216

17Q First examination report despatched

Effective date: 20010719

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20040930

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1011185

Country of ref document: HK